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1. INTRODUCTION 
1.1 Nucleic Acid Therapy 
Nucleic acid therapies have been considered as a confident chance for the 
treatment of life-threatening illnesses like cancer and genetic diseases1. The 
approach is based on technologies which deliver therapeutic nucleic acids into 
target tissues. Direct uptake into target cells is hindered because of the high 
molecular weight and the negative charge of nucleic acids. Nucleic acid therapies 
may occur within the patient’s body (in vivo) or outside the body (ex vivo) using 
isolated body cells. Therapeutic gene vectors can directly regulate gene expression 
as viral vectors encapsulating a gene expression vector2-3, or nonviral plasmid 
DNA (pDNA) expression vectors4. This strategy is promising for the treatment of 
inherent deficiencies by replacing either missing or unfunctional genes. In the 
case of DNA-based vectors, the nucleic acid needs to be introduced into the 
nucleus where it has to be maintained in accessible, active form to be expressed 
by the host cell transcription machinery.  
With time, other nucleic acid therapeutics have obtained increasing importance 
where nucleic acids can influence gene expression more indirectly than gene 
vectors do, most importantly small interfering RNAs (siRNA)5, but also single-
stranded oligonucleotides6-8, or immune system stimulating nucleic acids9. RNA 
interference (RNAi) mediated by 21-23 bp long double stranded siRNA operates 
in the cytosol10-12. Among the two strands the guide strand is designed to be 
complementary to the target mRNA, whereas the passenger strand normally has 
no complementarity. After cellular uptake the siRNA duplex is bound to several 
proteins like Ago2, Dicer and transactivating response RNA binding protein 
(TRBP), forming the RISC (RNA induced silencing complex) loading complex 
(RLC)13-14. Following 5´phosphorylation by ATP leads to unwinding of the 
siRNA and the cleavage of the passenger strand by Ago2, resulting in the mature 
RISC complex15. Complementary mRNA is recognized by RISC and 
consequently cleaved, by PIWI a subunit of Ago2, opposite to nucleotide 10 from 
the 5´end16-18. Active RISC complex can be recycled and repeatedly silence 
mRNA for several weeks. This demonstrates the high specificity and effectivity of 
siRNAs ideal for functional studies and therapeutic applications (Figure 1). 
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Similar effects are mediated by endogenous microRNAs19-20 (miRNA). Around 
1600 miRNAs have been found in humans (miRBase), regulating processes by 
translational repression. The main difference to siRNAs is the reduced 
complementarity of miRNAs to their target mRNAs resulting in translational 
repression without mRNA cleavage. miRNAs are explored as biomarkers21 for 
several illnesses and as targets for future therapies22.  
 
Figure 1 siRNA structure and mechanism: a) siRNA double strand consisting of passenger and guide 
strand with 3´overhangs. b) siRNA is phosphorylated after cellular uptake and loaded into the RISC complex. 
The guide strand mediates mRNA recognition and binding which leads in case of a perfect match to mRNA 
cleavage.(Modified from Shukla et al.23)  
Oligonucleotides (ON) are short single stranded nucleic acids or stabilized nucleic 
acid analogs with 20 or fewer bases. ONs can be used for several purposes, acting 
either in the cytosol or the nucleus. As antisense molecules they may bind to 
complementary mRNA and inhibit their translation or to miRNAs avoiding the 
inhibition24. ONs have also been used as agents in exon-skipping, to repair 
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defective mRNA by alternative splicing25, and as antagomirs, blocking natural 
micro RNAs6,26. 
1.2 siRNA Design 
Computational models have been developed to increase the likelihood of selecting 
effective and specific siRNAs27. Besides the selection of a siRNA sequence the 
stability of nucleic acids is critical because they are targets of ubiquitous 
occurring nucleases. Unmodified siRNAs have a serum half life of less than 15 
min, so they are impractical for therapeutic applications28. Modifications 
improving nuclease resistance are incorporated into the siRNA sequence either 
into the backbone, sugar, base or 3´and 5´ ends. Common backbone modifications 
include the replacement of non bridging oxygen by sulfur in the phosphate 
backbone (phosphorothioate) leading to improved nuclease resistance29. This 
phosphorothioate modification leads to less efficient RISC loading if used heavily 
in the guide strand. Widely used sugar modifications include 2´-OMe, 2´-fluoro 
and 2´-MOE30.  All of these sugar modifications increase the melting temperature 
and improve nuclease resistance. Another modification with high impact on the 
melting temperature is the incorporation of locked nucleosides31. In this method 
the position 2´and 4´of the ribose ring are linked through a methylene bridge. 
Furthermore, the thermodynamic properties of both siRNA ends influence RISC 
loading. Passenger strand modification increasing the 5´end melting temperature 
lead to selective incorporation of the guide strand32.  
In addition to stability reasons, modifications are necessary to combat the 
immunostimulatory effect of unmodified siRNAs. The effects are mainly 
mediated due to the activation of toll like receptors TLRs 3, 7 and 8 and cytosolic 
proteins like RIG-1 (retinoic acid inducible protein), or MDA-5 (melanoma 
differentiation associated protein)33. All these receptors can recognize double 
stranded RNAs and induce immune response mediated by interferons, cytokines 
and interleukin-6. For example TLR 3 is activated by double stranded nucleotides 
longer than 21-23bp, whereas the TLR 7 and 8 are activated by different motifs in 
the nucleotide sequence. Therefore, several modifications, for example 2´-OMe, 
are necessary to generate siRNAs without immunostimulatory effects. Great 
progress in the field of nucleic acid chemistry enabled the synthesis of nucleic 
acids with high serum stability and low immunostimulatory effects23,34-35. 
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1.3 Polymers and Oligomers for siRNA Delivery 
Nonviral delivery systems have been proposed as safer alternatives to viral 
vectors, because polymers and liposomes avoid the inherent immunogenicity of 
viral proteins and the expensive production in mammalian cell culture systems. 
Hence, several reasons have supported the use of polymers, including the fact that 
nucleic acids themselves are polymers which by the nature of their negative 
charges spontaneously form complexes (‘polyplexes’) with cationic polymers36. 
Nature utilizes the mechanism in multiple variations, for example in packaging 
genetic material with basic protein polymers into chromatin, strongly condensing 
DNA in sperm heads, or compacting DNA into virus core particles. Evolution has 
optimized such packaging into precise bioresponsive processes, where both 
assembly and disassembly can occur in a controlled manner. In contrast to nature, 
the first two to three decades of polymer based gene transfer development have 
yielded first encouraging, but still very primitive solutions. Low transfer 
efficiency of polyplexes, significant toxicity, polymer polydispersity and poorly 
understood delivery mechanisms are road blocks in the way towards 
therapeutically useful polymer formulations. Fortunately, recent developments 
present solutions for many of the obstacles37. Improved chemistry has resulted in 
the design of monodisperse polymer structures like dendrimers38 or other 
sequence defined oligomers39-41. Biodegradable oligomers with reduced 
cytotoxicity have been designed, allowing the incorporation of targeting ligands 
and surface shielding polymers. Shielded polyplexes minimize side effects due to 
unspecific interactions, whereas targeting ligands like small molecules or peptides 
allow specific interactions with cancer cells. Better understanding of delivery 
pathways and improved imaging methods42-45 contributed to the design of 
improved carriers for siRNA delivery. These bioresponsive carriers can change 
their properties, for example their conformation, through protonation, or by 
cleavage of covalent bonds in various biological compartments. This means the 
biological micro-environment can be used to trigger the oligomer and therefore 
the polyplex characteristics during the delivery process in a favorable dynamic 
way. Such dynamic processes are well-known from cellular entry of viruses, 
bacteria, toxins, and other cellular events. Major delivery tasks (Figure 2) are the 
transport of a siRNA without undesired interactions in blood and non-target sites. 
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In contrast, specific interactions with the target cell surface should trigger 
intracellular uptake followed by endosomal escape. 
 
Figure 2 Uptake process of functionalized polyplexes into the target cell: Hurdles for the efficient siRNA 
delivery are the stable binding of the nucleic acid, interactions with the cell surface, endosomal escape and 
the release of the siRNA into the cytosol (modified from D. Edinger et al.46) 
1.3.1  siRNA Packaging  
In the first instance the oligomer has to stably bind the nucleic acid outside the 
cell, to compact and protect the cargo from nucleases. Inside the cell the polyplex 
has to disassemble and release the siRNA, so the cargo can be effective. Different 
chemical characteristics outside the cell, in the endosome, the cytosol, and the 
nucleus have to manage the “assembly-disassembly” process. Therapeutic nucleic 
acids can be either noncovalently complexed or covalently conjugated to the 
carrier (Figure 3). Release of the nucleic acid at the target location from the 
polymer may proceed for example by exchange processes against polyions such 
as intracellular RNA47, by polymer degradation, or cleavage of the nucleic acid 
from the polymer attachment sites. 
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Figure 3 Assembly-disassembly process: Nucleic acids can be bound electrostatic or covalent by the 
polymers. Electrostatic assembled polyplexes can be stabilized by reversible caging. After entering the cell, 
the nucleic acid is released through exchange reactions or polymer degradation. (from D. Edinger et al.46) 
Electrostatic binding of siRNA to cationic oligomers is weaker as compared to 
pDNA, due to the lower number of negative charges in the short phosphate 
backbones. To overcome this hurdle chemically synthesized siRNAs can be 
covalently bound to their carriers48. This can be performed in a bioresponsive, 
reversible way, for example, disulfide bonds are stable in the bloodstream, but can 
be easily cleaved in the cytosol. Rozema et al. applied this strategy for the 
synthesis of “dynamic polyconjugates” of siRNA with polymers consisting of 
receptor-targeted, PEG-masked poly-butyl amino vinyl ethers49. In a mouse model 
they could show dose dependent hepatocyte-specific gene knockdown without 
detectable side effects, monitored by the control of liver enzymes and cytokine 
levels. Meyer et al. coupled siRNA with a 5´thiol modified sense strand to 
modified polylysine (PLL) with an endosomolytic peptide via bioreducible 
disulfide bonds50. The covalent character of the conjugates was demonstrated in 
that the conjugates were only cleavable through a combination of heparin with a 
reducing reagent. Nucleic acids modified with several functional domains like 
targeting, shielding and endosomal escape offer a promising approach for future 
siRNA therapeutics51. 
In contrast to the covalent binding of siRNA cationic polymers, primarily binding 
nucleic acids via electrostatic interactions with the negatively charged phosphate 
backbone have been synthesized. Nucleic acid binding depends on charge density, 
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size, shape, and flexibility/rigidity of polymers. For example, linear polymers 
such as poly(L)lysine52 or linear polyethylenimine (LPEI)53, branched structures 
such as branched PEI (brPEI)54, or dendrimers including polyamidoamines 
(PAMAMs) 55-58 have been used. In addition to electrostatic interaction, hydrogen 
bonding59 and hydrophobic polymer interactions60-61 can increase the stability of 
polyplexes, but stronger nucleic acid affinity does not necessarily directly 
correlate with higher transfection efficiency. Apparently an optimum has to be 
reached. Also the big difference in the size of different types of nucleic acids 
(pDNA with several thousand negative charges as opposed to siRNA with 42 
negative charges) has to be considered in this respect. For example, 22 kDa LPEI 
and 25 kDa brPEI have been successfully used for pDNA transfection, but do not 
effectively work for siRNA transfection62. Besides the weak silencing activity 
PEI-siRNA polyplexes are dissociated in full human serum monitored by 
fluorescence fluctuation spectroscopy63. Concatemerization of siRNA into larger 
structures (“sticky siRNA”)64 or change to other polymer backbones can partly 
but not completely overcome the problem.  
Bioresponsive carriers are a logical solution for the insufficient stability outside 
but too high stability inside the cell. Encouraging strategies including the design 
of biodegradable high-molecular weight polymers or polymer cages intracellularly 
degrading into low molecular weight nontoxic fragments have been applied. 
Polymers with cleavable bonds including hydrolysable esters65-67, acetal bonds 
degrading in the acidic environment of endosomes68-69, or disulfide bonds which 
are reduced in the cytosol have been synthesized70-72.  
Polyplexes can further be stabilized by caging, this means chemical crosslinking 
of the siRNA bound polymers via cleavable linkers. For example, Russ et al.73 
synthesized pseudodendrimers called HDO consisting of low molecular weight 
oligoethylenimine (OEI) and diacrylate esters delivering siRNA with moderate 
gene silencing efficiency in vitro. Lateral stabilization by crosslinking surface 
amines via bifunctional crosslinker (DSP) resulted in improved stability and high 
knockdown efficiency74. The design of pseudo amino acids suitable for solid-
phase-supported synthesis in combination with natural amino acids and fatty acids 
allowed the design of structure defined oligomers for siRNA transfection. From 
this approach nice structure activity relationships for effective siRNA carriers can 
be derived75. In contrast to the first generation of polydisperse carriers this new 
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concept also simplifies the GMP production of monodisperse carriers important 
for future clinical trials.    
1.3.2  Endosomal Escape  
Polyplexes are commonly taken up by a clathrin-, caveolin- dependent or related 
endocytic pathway, with polyplexes ending up inside endosomes. In time the 
endosomal pH decreases and endosomes fuse and mature to lysosomes. To deliver 
the siRNA into the cytosol, polyplexes have to escape this harsh environment. 
Either the carrier polymer itself or an endosomolytic domain has to mediate this 
process76-77. Because lipid membrane interaction and lysis would be a toxic event 
if occurring at the cell surface or mitochondrial membrane, the lytic activity has to 
be limited to the endosomes. Again bioresponsive polymers demonstrating an 
endosomal dependent lytic activity78-80 are the solution to this problem (Figure 4). 
In contrast, small polyplexes can show alternative uptake-mechanisms avoiding 
the endosomal pathway81-82. 
 
Figure 4 Endosomal escape: a) mediated by the proton sponge effect, b) pH dependent lytic activity, c) pH 
triggered lytic activity, d) or by a reductive mechanism (from D. Edinger et al.46). 
PEI or PAMAM dendrimers are highly active in gene transfer, because these 
polymers are “proton sponges”, displaying about 20% protonation of nitrogens at 
neutral pH (important for nucleic acid binding), which increases with endosomal 
acidification. The increased density of positive charges leads to an influx of 
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chloride and water into the endosome83. Finally, as consequence of the so called 
“proton sponge effect”, the endosome bursts due to the elevated osmotic pressure 
and the membrane destabilizing effect of positively charged polymer domains. 
Efficient endosomal escape however, still presents a bottle neck to be optimized 
for the delivery process of therapeutic nucleic acids. For PEI the window between 
effective dose for endosome disruption and cytotoxic dose is very narrow. For 
efficient siRNA delivery brPEI 25 kDa was modified with succinic acid (PEI-
Succ10)54. This modification diminishes positive charges at neutral pH, but the 
polymer still presents a proton sponge, containing both protonable carboxylates 
and nitrogens. Because of a far lower cytotoxicity it is possible to apply higher 
doses of the polymer and to improve endosomal escape in this way.  
In contrast, polymers like polylysine (PLL) cannot destabilize endosomes 
themselves. Hence, natural or synthetic lytic domains must be incorporated into 
such carriers. For example viruses have developed strategies to efficiently 
overcome the endosomal barrier. In several cases fusion peptides, such as those 
occurring at the N-terminus of the influenza virus haemagglutinin subunit 2 
(HA2), can generate a fusion pore in the membrane, triggering viral and host 
membrane fusion. Plank et al. suggested the HA2 subunit Inf7 consisting of the 23 
amino terminal amino acids as pH specific endosome disruptive peptide84.  Also 
lipid-free viruses such as adenovirus or rhinovirus have developed endosomal 
membrane destabilizing peptides. Therefore, incorporation of synthetic analogs of 
viral peptides, whole inactivated virus particles2, recombinant fusion proteins 
derived from bacteria78, toxins and other natural sources have strongly enhanced 
endosomal escape84-87.  
1.3.3  Polyplex Shielding 
Electrostatic siRNA binding generally results in positively charged polyplexes. 
This positive charge enhances target cell interaction, but also provokes unintended 
interactions with biological surfaces including protein surfaces, extracellular 
matrix and nontarget cells. Shielding the surface charges of polyplexes provides 
improved solubility, reduced aggregation with serum proteins, better 
biocompatibility, and prolonged blood circulation. For this reason the addition of 
Polyethylenglycol (PEG) has been broadly explored. The shielding domain can 
either be bound through, covalent incorporation of PEG to the polymeric carrier88-
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92
, direct PEGylation of the nucleic acid51,93-95, or by PEGylation after polyplex 
formation96-97. In addition to PEG, other hydrophilic molecules like 
polyhydroxypropylmethacrylate (pHPMA)98-99, hyaluronan100  or hydroxyethyl 
starch (HES)101 have been applied reducing the positive surface charge of 
polyplexes. HES is a biodegradable shield, therefore shielded particles are slowly 
deshielded in the circulation by α-Amylase. In contrast to the stable, irreversible 
surface shielding of other shielding agents, this was advantageous for in vivo 
applications enabling the interaction with cell surfaces and lipid membranes102.  
 
Figure 5 Different PEGylation methods: Polymers can be PEGylated through diversely cleavable linkers. 
The dePEGylation of these cleavable linkers may take place in the microenvironment of the tumor 
(enzymatic), or inside the endosomes (ionic, acid labile) (from D. Edinger et al.46). 
For PEGylated polyplexes bioresponsive deshielding strategies have been 
developed as possible solutions (Figure 5), capitalizing location-specific changes 
in enzymatic activity103, disulfide reducing potential99 or pH89,93,96,104. Another 
method to regain particle cell interactions is the incorporation of targeting 
moieties.  
1.3.4  Receptor Targeting 
In many types of cancer certain surface receptor levels are upregulated. Therefore, 
targeting these cell surface receptors offers the possibility to address defined cells 
in a tissue. Especially shielded particles used for in vivo application profit from 
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the incorporation of targeting ligands. Several ligands have been shown to be 
suitable for targeted gene delivery, these are for example vitamins, carbohydrates, 
peptides, proteins and glycoproteins, antibodies in various modifications, small 
molecules, or nucleic acid aptamers.  
For example the epidermal growth factor receptor (EGFR) is upregulated in many 
cancers, like lung cancer, colorectal cancer and glioblastomas. For this reason 
various EGFR binding molecules, including EGF recombinant protein, EGFR 
binding antibodies, or EGFR binding phage derived peptides105 have been 
explored in polyplexes as interesting targeting ligands. Targeting the EGFR also 
accelerates the cellular uptake of polyplexes. Single particle tracking allowed 
distinguishing between three phases during the uptake process. In the first phase 
particle movement is slow, it includes all processes up to the internalization of the 
polyplexes. The following second phase is characterized by diffusion processes in 
the cytosol, while in the third phase polyplexes are rapidly transported along 
microtubules. Cellular uptake of EGFR targeting complexes resulted in a 
shortening of phase one and so contributed to a faster uptake of the polyplexes. 
Another often upregulated receptor is the transferrin receptor (TfR), a 
glycoprotein responsible for iron ion transport in mammals. After binding to the 
TfR, the complex consisting of receptor and ligand is absorbed by the cell through 
a clathrin dependent pathway and then integrated into the endocytic cycle. For this 
reason Tf has been frequently used as a targeting ligand for siRNA delivering 
polyplexes106-109. Tietze et al used TfR targeted, PEG-shielded crosslinked 
oligoethylenimines for siRNA delivery into Neuro2A tumor bearing mice109. 
Davis and colleagues110-112 used Tf targeted cyclodextrin to deliver siRNA, 
targeting the M2 subunit of ribonucleotide reductase. These targeted polyplexes 
were evaluated in human clinical trials and they were the first polymeric carriers 
to show gene knockdown in solid human tumors113.  
Apart from protein and peptide ligands, also low molecular weight targeting 
ligands such as the vitamin folic acid have been used for nucleic acid delivery. 
The related folate receptor (FR) is upregulated in various cancers, mediating 
cellular uptake of the vitamin folic acid via a caveolin mediated pathway114. 
Thomas et al. could show the impressive targeting efficacy of folic acid using 
siRNA covalently bound to folate via a short linker. The particles specifically 
bind to tumor tissues in vitro and in vivo, but failed to show gene transfer activity 
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because of lacking carriers115. Dohmen et al. combined siRNA linked to folic acid 
with defined oligomers synthesized by solid-phase-supported macromolecule 
assembly. This combination showed great and selective uptake and strong marker 
gene knockdown in folic acid overexpressing KB cells51,116. Methotrexate (MTX) 
has high structure similarity to folic acid and can also be used as a targeting 
ligand117 combining the use of a classical chemotherapeutic with the novel 
approach of RNAi. 
1.4 Target Genes  
Selection of target genes suitable for therapeutic assays is very complex. Clear 
correlation between target mRNA and illness have to be identified. For example 
the knockdown of Apolipoprotein B mRNA in the liver led to reduced cholesterol 
levels in the bloodstream of mice118. Reduced mRNA levels were detectable in the 
liver for several days up to some weeks because target gene knockdown did not 
affect cell viability119. In contrast, the treatment of cancer cells commonly aims at 
killing the tumor cell. Therefore, target gene knockdown is only detectable for a 
short period of time.  
Eg5 (Kif11, KSP) was suggested as a therapeutic target for cancer therapy by our 
collaboration partner Axolabs (formerly Roche Kulmbach)120-121. Eg5 is involved 
in the assembly and organization of the mitotic spindle apparatus, a self-
assembled and dynamic microtubule based structure which is important for 
chromosome segregation in dividing cells122. During mitosis Eg5 is responsible 
for centrosome separation thus playing a pivotal role in cell division. In 
consequence, Eg5 knockdown blocks mitosis and leads to G2 arrest especially 
harming rapidly dividing cancer cells. The mitotic blockade comparable to the 
small molecule monastrol leads to the typic “aster formation” of nuclear DNA123. 
In consequence reduced Eg5 protein levels hinder mitosis and lead to cell death. 
But also high Eg5 levels lead to spindle defects, genetic instability, and tumors, 
demonstrating the important role of Eg5 during mitosis124. Similar to the effects of 
Eg5 knockdown classical chemotherapeutics like vinca alkaloids and taxanes also 
influence the microtubule assembly and disassembly. 
Introduction     13 
 
 
Figure 6 Role of Eg5 during mitosis: Tetrameric Eg5 motors help to organize microtubules forming the 
mitotic spindle. Eg5 moves towards the plus-ends of antiparallel microtubules, leading to the poleward drift 
of the centrosomes (modified from Valentin et al.122). 
Another therapeutic relevant target is the RAS related nuclear protein (Ran)125-126. 
As a member of the RAS superfamily, Ran mediates nuclear import and export of 
proteins and oligonucleotides during interphase. Furthermore Ran is involved in 
DNA synthesis and in cell cycle progression127-128. Ran can exist either in GTP or 
GDP bound form and has an intrinsic GTPase activity. Activated due to the 
interaction with Ran GTPase activating protein (Ran-GAP), Ran-GTP is 
converted into Ran-GDP. Ran-GAP is located in the cytosol reducing Ran-GTP 
levels in the cytosol. Ran-GEF (RCC1) another protein involved in the Ran cycle 
is located in the nucleus mediating the exchange of GDP and GTP. Hence, the 
localisation of the two proteins leads to an imbalance of Ran-GTP in the nucleus 
and cytosol. This concentration gradient is used for active transport of cargo into 
or out of the nucleus. High Ran expression levels are associated with cancer129-130, 
therefore Ran is used as a target for siRNA therapy. 
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Figure 7 Role of Ran: Ran cycle with high Ran-GDP levels in the cytosol mediated by Ran-GAP and high 
Ran-GTP levels in the nucleus due to Ran-GEF expression. This concentration gradient enables directed 
transport of cargo into the nucleus or the cytosol. 
In contrast, marker genes are usually selected for polymer screening assays, 
enabling an easy quantification of mRNA knockdown75,131. Therefore, the marker 
genes eGFP or Luciferase are commonly used. After establishing cell lines 
expressing one or both of this marker genes, mRNA knockdown can be easily 
detected.   
1.5 Aims of the Thesis 
Discovery of RNAi was a major breakthrough for the research of biological 
processes and may become an option for the treatment of severe diseases. 
Especially as siRNAs have the potential to be effective where classical 
therapeutics, antibodies, and small molecules fail. Target specificity on the one 
hand and the possible selection of several ten thousand target genes on the other 
hand are making siRNAs a promising approach for future therapies. However, the 
broad application of siRNAs is hampered by its size and negative charge. These 
limitations can either be overcome by minimizing the size and charge of the 
nucleic acids, by the use of carriers or by a combination of both. The current 
thesis focusses on the characterization of oligomeric carriers suitable for 
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successful siRNA transfection in vitro and in vivo. For this purpose many 
different biodegradable oligomeric carriers have been synthesized by solid-phase-
supported synthesis. This novel strategy allowed the selective incorporation of 
diverse components like cysteines, tyrosines (stabilization) and histidines 
(improved endosomal escape) into structures with different topologies. The first 
aim of the thesis was the in vitro evaluation of numerous siRNA carriers to define 
several requirements for successful in vitro gene silencing. Improved 
understanding of the requirements led to the synthesis of carriers with higher 
transfection efficiency and greater stability against serum proteins. The second 
aim of the thesis was the in vivo evaluation of different oligomers with successful 
gene silencing in vitro. For this reason, assays for the detection of fluorescence 
labeled siRNAs in sections or living animals had to be established. Thereby, the 
distribution and clearance of different polyplexes could be compared in living 
animals or tumor sections. Furthermore, altered transfection efficiency of in vitro 
active carriers should be compared in an intratumoral assay. Therefore, two 
therapeutic siRNAs were explored in vitro for their target specificity by qPCR and 
Western blot and their knockdown related cytotoxicity by CellTiter Glo assays. 
Both therapeutic siRNAs were also evaluated in an intratumoral assay and Ran 
siRNA was chosen for the comparison of different oligomers. The intratumoral 
comparison of different polyplexes is an important step towards the in vivo use of 
siRNA therapeutics. The third aim of the thesis was the evaluation of 
multifunctional siRNA polyplexes in vitro and in vivo. Folic acid bound to an 
oligomeric backbone was used as a targeting ligand, whereas siRNA´s passenger 
strand was modified with the endosomolytic peptide Inf7 for improved endosomal 
escape. At first suitable cell lines overexpressing the folic acid receptor had to be 
evaluated. Furthermore, in vitro transfection experiments were conducted to 
demonstrate the activity of the different functional domains. The focus was the in 
vivo application of the polyplexes to monitor circulation halflife, targeting and the 
establishment of histological assays to analyze target gene knockdown. Besides 
the in vivo evaluation of folic acid linked oligomers the in vitro classification of 
novel methotrexate (MTX) containing targeting oligomers was performed. The 
assays should demonstrate the effectivity and the targeting efficiency of polymer 
linked MTX. 
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2  MATERIALS AND METHODS 
2.1 Materials 
Consumables (dishes, well plates, flasks) were obtained from NUNC (Germany) 
or TPP (Switzerland). Cell culture 5 x lysis buffer and D-luciferin sodium salt 
were obtained from Promega (Germany). Cell culture media, antibiotics, stable 
glutamine, and fetal calf serum (FCS) were purchased from Invitrogen (Germany) 
and Hepes was purchased from Biomol GmbH (Germany).  
2.2 siRNAs 
The applied siRNA duplexes were ordered from Dharmacon (ThermoFisher, 
USA) or Axolabs (Germany, former Roche Kulmbach). They were diluted in 
RNAse free water and the stocks (20 µg/µl) were stored at -80°C. For use in cell 
culture, stocks were diluted to 0,5 µg/µl, whereas for in vivo use stocks were 
diluted to 2-5 µg/µl. RAN siRNA was ordered in in vivo qualities and their 
sequences is shown in the table below. Small letters represent 2-Methoxy sugar 
modifications and s represents phosphorothioate backbone modifications. Some 
siRNAs were further modified with Inf7 peptide by C. Dohmen to demonstrate 
lytic activity in the endosomes116.   
siRNA Target Supplier siRNA sequence 
siGFP GFP Axolabs AuAucAuGGccGAcAAGcAdTsdT (Sense) 
UGCUUGUCGGCcAUGAuAUdTsdT (Antisense) 
siControl  Axolabs AuGuAuuGGccuGuAuuAGdTsdT 
CuAAuAcAGGCcAAuAcAUdTsdT 
siAHA1 AHA1 Axolabs GGAuGAAGuGGAGAuuAGudTsdT 
ACuAAUCUCcACUUcAUCCdTsdT 
siEg5 Eg5/KSP Axolabs ucGAGAAucuAAAcuAAcudTsdT 
AGUuAGUUuAGAUUCUCGAdTsdT 
siRan Ran Dharmacon UAGUACUGAAGAUUCUUCUUU 
AGAAGAAUCUUCAGUACUAUU 
siGlo  Dharmacon AUGUAUUGGCCUGUAUUAG 
(Cy3)thiol-AUGUAUUGGCCUGUAUUAG 
siAHA1-Cy5  Axolabs GGAuGAAGuGGAGAuuAGudTsdT 
(Cy5)(NHC6)ACuAAUCUCcACUUcAUCCdTsdT 
siAHA1-Cy7  Axolabs GGAuGAAGuGGAGAuuAGudTsdT 
(Cy7)(NHC6)ACuAAUCUCcACUUcAUCCdTsdT 
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siGFP-Inf  Axolabs (C. Dohmen) (Inf-SSC6)AuAucAuGGccGAcAAGcAdTsdT 
UGCUUGUCGGCcAUGAuAUdTsdT 
siControl-Inf  Axolabs (C. Dohmen) (Inf-SSC6)AuGuAuuGGccuGuAuuAGdTsdT 
CuAAuAcAGGCcAAuAcAUdTsdT 
siEg5-Inf  Axolabs (C. Dohmen) (Inf-SSC6)ucGAGAAucuAAAcuAAcudTsdT 
AGUuAGUUuAGAUUCUCGAdTsdT 
2.3 Oligomers 
Oligomers were synthesized by solid-phase-supported synthesis as previously 
described116,132-133. The table demonstrates polymer sequences, polymer shapes 
and polymer IDs. Freeze dried oligomers were diluted in deionized, sterile water 
for all experiments. 
Polymer ID Polymer shape Polymer sequence 
49 T-Shape C-Stp2-[(OleA)2-K]K-Stp2-C  
229 i-Shape C-Stp3-C-K-(LinA)2 
386 Branched [(C-Stp3)2]K-Stp3-C 
216 T-Shape A-Stp2-[(OleA)2-K]K-Stp2-A  
332 T-Shape Y3-Stp2-[(OleA)2-K]K-Stp2-Y3  
454 T-Shape C-Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-C  
468 T-Shape C-Stp2-[(Y3)2-K]K-Stp2-C 
333 T-Shape Y3-Stp2-[(Y3)2-K]K-Stp2-Y3  
464 T-Shape C-Y3-Stp2-[(Y3)2-K]K-Stp2-Y3-C  
356 Targeted Fol-PEG24-K(STP4C)2  
188 Targeted A-PEG24-K(STP4C)2  
482 Targeted Fol-PEG48-K(STP4C)2  
483 Targeted Fol-PEG72-K(STP4C)2  
646 Targeted A-PEG120-K(STP4C)2 
647 Targeted A-PEG192-K(STP4C)2  
484 Targeted Fol-PEG24-K(STP4Y3C)2  
481 Targeted Fol-PEG24-K(STP4K(KCapA)2C)2  
480 Targeted Fol-PEG24-K(STP4K(KSteA)2C)2  
638 Targeted K(PEG24-MTX)-K(STP4-C)2 
639 Targeted K(PEG24-E2-MTX)-K(STP4-C)2 
640 Targeted K(PEG24-E4-MTX)-K(STP4-C)2 
641 Targeted K(PEG24-E6-MTX)-K(STP4-C)2 
642 Targeted K(PEG24-αMTX)-K(STP4-C)2 
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2.4 Polyplex Formation  
Polyplex were prepared as follows, unless the use of different solvents is 
indicated. 500 ng siRNA per well or per slot for untargeted oligomers, 200 ng 
siRNA per well or per slot for targeted or 50 µg siRNA per animal and the 
calculated amount of oligomer were diluted in separate Eppendorf tubes each in 
HBG (20 mM Hepes buffered 5% glucose pH 7.4). The amount of polymer was 
calculated as follows:  
		 =
m	siRNA	 	∗ 	negative	charges	siRNA	 ∗ 	


	 ∗ M	Oligomer	
M	siRNA		∗ 	protonable	amines	Oligomer	
 
For screening experiments several N/P (protonable amines/Phosphates) were 
tested. The oligomer solution was added to the siRNA, rapidly mixed by gently 
pipetting up and down (no air bubbles) and incubated for at least 45 min at room 
temperature in order to allow stable polyplexes formation. 
2.5 Biophysical Characterization  
2.5.1 Particle Size and Zeta Potential Measurement  
Particle sizes of siRNA formulations were measured by dynamic-laser-light 
(DLS) scattering using a Zetasizer Nano ZS (Malvern Instruments, U.K.). siRNA 
polyplexes N/P 12 (10 µg siRNA in 50 µl buffer) were prepared according to the 
previous mentioned formula and mixed in 20 mM Hepes pH 7.4 buffer. Before 
DLS measurement polyplexes were diluted 1:20 in Hepes pH 7.4 and measured in 
a folded capillary cell (DTS1060) with laser light scattering using a Zetasizer 
Nano ZS with backscatter detection. Samples were measured 3 times each with 10 
sub-runs of 10 seconds. Results were displayed as Z-average, whereby the 
standard deviation shows the difference between the 3 runs. The zeta potentials 
were also analyzed with the Zetasizer Nano ZS. Samples were measured 3 times, 
with 10 up to 30 sub-runs of 10 s at 25°C. 
2.5.2 Agarose Gel Shift Assay  
For gel shift assays a 2% agarose gel was prepared by dissolving 2 g ultrapure 
agarose in 100 ml TBE buffer (trizma base 10.8 g, boric acid 5.5 g, disodium 
EDTA 0.75 g and 1 l of water). The mixture was heated in a microwave to 
dissolve the agarose in TBE buffer. After the solution cooled down 80 µl GelRed® 
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(VWR, USA) were added for the detection of nucleic acids and the clear solution 
was filled into an electrophoresis chamber. Polyplexes in different N/P ratios, 
containing 500 ng siRNA in 20 µl HBG mixed with 5 x loading buffer (prepared 
from 6 ml of glycerine, 1.2 ml of 0.5 M EDTA, 2.8 ml of H2O, 0.02 g xylene 
cyanol) were placed into the sample pockets and electrophoresis was performed at 
120 V for 40 min. 
2.5.3 Serum Stability Assay 
A 2% agarose gel was prepared as described above. For the stability assays 
500 ng siRNA and the oligomer at N/P 12 were diluted in separate tubes to a total 
volume of 12.5 µl in 20 mM Hepes pH 7.4. The nucleic acid solution was added 
to the diluted polycation, mixed and incubated for 45 min at room temperature. 
Afterwards fetal calf serum (FCS) was added to the samples. All samples had a 
final concentration of 90% FCS. The samples were incubated either at room 
temperature or 37°C for different time points. After 0, 10, 30, and 90 min, 4 µl 
loading buffer were added and 20 µl of the samples were placed into the sample 
pockets. Electrophoresis was performed at 120 V for 40 min.  
2.6 Biological Chararacterization in vitro  
2.6.1 Cell Culture 
Different cell lines were used and cultured in the appropriate medium, except for 
targeting experiments where cells were cultured in folic acid free medium if 
possible. All media were supplemented with 10% FCS, 4 mM stable Glutamine, 
100 U/ml Penicillin and 100 µg/ml Streptomycin (cell lines for animal 
experiments were cultured without antibiotics). The cells were cultured in 
ventilated flasks inside incubators at 37°C with 5% CO2 in a humidified 
atmosphere. Cell lines were allowed to grow until 80% confluence and splitted 
when necessary. Cell lines stably expressing the eGFPLuc gene were generated by 
A. Cengizeroglu through lentiviral transduction and eGFPLuc positive cells were 
sorted by J. Ellwart. 
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Cell line Origin Media eGFP/Luc 
Neuro2A Murine; Neuroblastoma DMEM + 10%FCS + 1%Glutamine 
+ 1% P/S 
eGFPLuc 
HUH7 Human; Hepatocellular carcinoma DMEM/HAM´s F12 + 10%FCS + 
1%Glutamine + 1% P/S 
Luc 
HEPG2 Human; Hepatocellular carcinoma DMEM + 10%FCS + 1%Glutamine 
+ 1% P/S 
eGFPLuc 
KB Human; Cervical carcinoma RPMI + 10%FCS + 1%Glutamine + 
1% P/S 
eGFPLuc 
IGROV Human; Ovarian carcinoma RPMI + 10%FCS + 1%Glutamine + 
1% P/S 
eGFPLuc 
A431 Human; Epidermoid carcinoma DMEM + 10%FCS + 1%Glutamine 
+ 1% P/S 
 
A549 Human; Alveolar 
Adenocarcinoma 
DMEM + 10%FCS + 1%Glutamine 
+ 1% P/S 
 
MCF7 Human; Breast cancer DMEM + 20%FCS + 1%Glutamine 
+ 1% P/S 
 
MDA-MB 231 Human; Breast Cancer L15 + 10%FCS + 1%Glutamine + 
1% P/S 
 
Az521 Human; Gastric Adenocarcinoma EMEM + 10%FCS + 1%Glutamine 
+ 1% P/S 
eGFPLuc 
2.6.2 GFP Knockdown Assay 
Gene silencing experiments were by default performed in stably transfected 
Neuro2A-eGFPLuc or KB-eGFPLuc cells using 500 ng (untargeted oligomers) or 
200 ng (targeted oligomers) siRNA per well of either GFP siRNA for silencing of 
the eGFPLuc protein, or control siRNA for the detection of polyplex related 
cytotoxicity (siRNA sequences are displayed in the previously mentioned table). 
Experiments were performed in 96-well plates with 5 × 103 cells per well. After 
seeding, the cells were incubated for 24 h to guarantee proper cell adhesion. 
Before transfection the medium was replaced with 80 µl fresh growth medium 
containing 10% FCS. Transfection complexes for siRNA delivery were formed in 
20 µl HBG at different N/P and added to the wells in triplicates. Untargeted 
polyplexes were incubated for 48 h while targeted polyplexes were incubated for 
45 min on the cells. After 48 h cells were lysed with 100 µl cell lysis buffer. 
Luciferase activity in the cell lysate was measured using a luciferase assay kit 
(100 µl Luciferase Assay buffer, Promega, Germany) and a Centro LB 960 plate 
reader luminometer (Berthold Technologies, Germany). The relative light units 
(RLU) are presented as percentage of the luciferase gene expression obtained with 
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buffer treated control cells. 
2.6.3 Quantitative Real Time Polymerase Chain Reaction 
1.5 × 105 Neuro2A cells per well were seeded in 2000 µl medium (DMEM with 
10% FCS) using 6-well plates. After 24 h, medium was replaced with 900 µl fresh 
medium (DMEM with 10% FCS). Polyplexes were prepared in a total volume of 
100 µl as described above and added to the wells after 45 min incubation time. All 
experiments were performed in triplicates using either Eg5 siRNA, Ran siRNA or 
control siRNA (sequences see above). Transfected cells were incubated for 24, 48, 
and 72 h without medium change. After 24, 48, and 72 h cells were lysed and total 
RNA was isolated using High Pure RNA Tissue Kit® (Roche, Germany) and 
transcribed with the Transcriptor High Fidelity cDNA Synthesis Kit® (Roche, 
Germany) according to the manufacturer’s protocol. Quantitative real-time PCR 
was performed using UPL Probes and Probes Master (both Roche, Germany) on a 
LightCycler 480® system (Roche, Germany) with GAPD as housekeeper. Primers 
used include murine GAPD (ready to use Universal Probe library assay Roche), 
Eg5 (UPL Probe #100) forward: TTCCCCTGCATCTTTCAATC, reverse: 
TTCAGGCTTATTCATTATGTTCTTTG; Ran (UPL Probe #2) forward: 
ACCCGCTCGTCTTCCATAC, reverse: ATAATGGCACACTGGGCTTG. 
Results were analysed using the ∆CT method, therefore CT values of the 
housekeeper were subtracted from CT values of the gene of interest. The ∆CT 
values of control transfected cells were set to 100% and compared to Eg5 and Ran 
siRNA transfected cells. 
2.6.4 Western Blot 
1.5 × 105 Neuro2A cells per well were seeded in 2000 µl medium (DMEM with 
10% FCS) using 6-well plates. After 24 h, medium was replaced with 900 µl fresh 
medium (DMEM with 10% FCS). Transfection complexes were prepared in a 
total volume of 100 µl as described above. After 24, 48, and 72 h cells were lysed 
and total protein concentration was determined using a BCA (Bicinchonic acid) 
assay. 50 µg of protein per lane were separated by SDS-PAGE under reducing 
conditions, transferred on a nitrocellulose membrane, and blocked with NET 
Gelatine or milk powder (5% in TBST) for 1 hour at room temperature. 
Immunostaining was performed using either primary Ran anti rabbit antibody 
(Cell Signaling, Germany; 1:500), or Eg5 anti goat antibody (Santa Cruz 
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Biotechnology Inc., USA; 1:200) or GAPD anti rabbit antibody (Cell Signaling, 
Germany; 1:5000) overnight at 4°C. After the incubation with primary antibodies 
membranes were washed 3 times with NET Gelatine or TBST (Tris buffered 
saline and Tween 20) before incubating with a peroxidase labeled secondary 
antibody (Vector Laboratories, France) for 1 h. After another 3 washing cycles, 
proteins were visualized using Lumi-Light Western blotting substrate (Roche, 
Germany). Blots were quantified using Image J software (NIH, USA). 
2.6.5 Flow Cytomerty 
2.6.5.1 Receptor Level Studies 
Cell lines expressing the folic acid receptor were identified by flow cytometry. 
For this experiment cells were either cultivated in the previously mentioned cell 
culture medium or in folate free RPMI medium if possible. 1 x 106 cells were 
collected in 150 µl FACS buffer and 10 µl APC-conjugated anti folic acid 
receptor 1 mouse IgG1 (R&D Systems, USA) were added. After 30 min cells were 
washed twice with FACS buffer, resuspended in 500 µl FACS buffer and 
analyzed using a Cyan® ADP flow cytometer (Dako, Germany). Doublets were 
discriminated by accurately gating forward/sideward scatter and forward 
scatter/pulse width, while counterstaining with DAPI (4,6-Diamidin-2-phenylindol) 
allowed distinguishing between dead and living cells. The amount of folic acid 
receptor positive cells was analyzed through excitation of the dye at 635 nm and 
detection of emission at 665/20 nm. For each sample 5 x 104 events were counted 
using Summit® software (Summit, USA) and evaluated using FlowJo® software 
(FlowJo, USA).     
2.6.5.2 Receptor Binding Studies 
Polyplex uptake into cells was monitored by flow cytometry. For uptake 
experiments 5 x 104 cells per well were seeded in 1000 µl medium using 24-well 
plates. 24 h later the medium was replaced with 450 µl fresh growth medium and 
polyplexes containing Cy5 labeled siRNA mixed in a total volume of 50 µl were 
added. The 24-well plates were incubated on ice for 45 min to hinder polyplex 
uptake. After 45 min medium was removed and cells were washed twice with cold 
PBS (phosphate buffered saline) and trypsinized. Trypsin was inactivated with 
1000 µl FACS buffer (10% FCS in PBS) and the cells were centrifuged 
(2000 rpm; 5 min). After two washing cycles with 1000 µl PBS the cells were 
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resuspended in 400 µl FACS buffer and analyzed using a Cyan® ADP flow 
cytometer (Dako, Germany). The amount of Cy5 positive cells was analyzed 
through excitation of the dye at 635 nm and detection of emission at 665/20 nm. 
Doublets were discriminated by accurately gating forward/sideward scatter and 
forward scatter/ pulse width, while counterstaining with DAPI (4,6-Diamidin-2-
phenylindol) allowed distinguishing between dead and living cells. For each 
sample 1 x 104 events were counted using Summit® software (Summit, USA) and 
evaluated using FlowJo® software (FlowJo, USA).     
2.6.5.3 Cell Cycle Measurement  
2.5 × 104 Neuro2A cells per well were seeded in 1000 µl medium (DMEM with 
10% FCS) using 24-well plates. After 24 h, medium was replaced by 450 µl fresh 
medium (DMEM with 10% FCS). Transfection complexes were prepared as 
described above. After the incubation time (24, 48, 72 h) cells were trypsinized, 
collected in their culture medium and centrifuged (2000 rpm; 5 min). The 
supernatant was discarded and the cell pellet was washed with PBS before 
staining with propidium iodide solution (0.1% sodium citrate; 0.1% Triton-X100; 
50 µg/ml propidium iodide in millipore water). After 3 h 1000 µl PBS were 
added, cells were centrifuged (2000 rpm; 5 min), resuspended in 500 µl PBS and 
measured with a Cyan® ADP flow cytometer (Dako, Germany). Doublets were 
discriminated by accurately gating forward/sideward scatter and forward scatter/ 
pulse width. The DNA content was measured through excitation of the dye at 
488 nm and detection of emission at 613/20 nm. For each sample 1 x 104 events 
were counted using Summit® software (Summit, USA) and evaluated using 
FlowJo® software (FlowJo, USA).     
2.6.6 Fluorescence Microscopy 
1 × 104 Neuro2A, KB or IGROV cells per well were seeded in 200 µl medium 
(DMEM or RPMI with 10% FCS) using 8-well Lab-tek® chamberslides (Sigma-
Aldrich, USA). 24 h after seeding medium was replaced by 180 µl fresh medium 
and 20 µl polyplex solution were added (in HBG). Cells transfected with 
polyplexes containing either Eg5 or control siRNA were incubated for 24 h 
(untargeted polyplexes) or 45 min (targeted polyplexes). After the incubation time 
medium was removed and cells were washed with 200 µl PBS and fixed with 4% 
paraformaldehyd (PFA). Fixed cells were stained with DAPI to visualize the DNA 
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and results were documented using Zeiss Axiovert 200 (fluorescence microscope, 
Carl Zeiss AG, Germany). 
2.6.7 CellTiter Glo Assay 
5 × 103 Neuro2A cells per well were seeded in 100 µl medium (DMEM with 10% 
FCS) using 96-well plates. 24 h later, medium was replaced by 80 µl fresh 
medium (DMEM with 10% FCS) and 20 µl polyplex solution were added. After 
24, 48, and 72 h 100 µl CellTiter Glo solution (Promega, USA) was added and the 
luminescence was recorded with a Luminometer (Lumat LB9507, Berthold, 
Germany).  
For the detection of methotrexate (MTX) related toxicity cells were also seeded in 
a 96-well plate as described above. To determine IC50 values of MTX, MTX 
targeted oligomers or MTX polyplexes the culture medium was also replaced after 
24 h by fresh medium containing different concentrations of the previously 
mentioned therapeutics. After 48 h 100 µl CellTiter Glo® solution (Promega, 
USA) was added and the luminescence was recorded with a Luminometer (Lumat 
LB9507, Berthold, Germany). IC50 values were calculated with GraphPad Prism® 
(GraphPad, USA) software. 
2.6.8 Dihydrofolatereductase Activity Assay 
Inhibition of dihydrofolatereductase (DHFR) through MTX or MTX containing 
oligomers was measured by a spectroscopic assay. All reagents despite the tested 
oligomers were supplemented in the dihydrofolate reductase assay kit (Sigma-
Aldrich, USA). The reduction of absorption is measured by a photospectrometer 
at 340 nm, as DHFR catalyses the reduction of dihydrofolic acid to tetrahydrofolic 
acid in a NADPH dependent reaction. MTX blocks the activity of the enzyme 
DHFR, in consequence the reduction of dihydrofolic acid is hampered leading to 
higher concentrations of NADPH/H+ and therefore higher absorption values at 
340 nm after 2.5 min. The absorption values without inhibition decreased and the 
reduction was compared to the reduction with inhibitor.  
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2.7 Biological Characterization in vivo  
2.7.1 Mouse Strains  
Female 5 week old A/J mice were purchased from Harlan Winkelmann 
(Germany) and female 5 week old NMRI-nu (nu/nu) from Janvier (France). After 
arrival the mice were allowed to acclimatize for one week before starting the 
experiments. All mice were housed in individually vented cages with food and 
water provided ad libitum and a 12 h day and night cycle. Animal experiments 
were performed according to guidelines of the German law of protection of 
animal life and were approved by the local animal experiments ethical committee.  
2.7.2 Histological Studies 
For histological assays 1 x 106 Neuro2A cells or 5 x 106 KB cells in a volume of 
150 µl PBS were subcutaneously injected into the left flank of A/J mice 
(Neuro2A) or NMRI mice (KB). After tumors reached a volume of about 
200 mm3 (10 days) polyplexes were injected.   
2.7.2.1 Polyplex Distribution 
Polyplexes distribution was measured by incorporation of Cy3 labeled siRNA into 
the intravenously injected polyplexes (N/P 12). Mice were sacrificed 1 h after tail 
vein injection of the polyplexes mixed in a total volume of 250 µl and organs 
(tumor, lung, liver, kidneys) were harvested. Organs were immobilized in 
TissueTek® and 5 µm fine sections were cut using a cryotom (Leica CM3050 S 
Leica Microsystems GmbH, Germany). Slices were stained with Hoechst 33342 
dye, sealed with FluorSave (Calbiochem, Merck Group, Germany) and analyzed 
with Zeiss Laser Scanning Microscope LSM510 Meta (Carl Zeiss, Germany). 
2.7.2.2 Aster Formation 
Mice were intravenously injected twice with Eg5 siRNA (for oligomers 422 and 
188 Inf7 modified siRNAs were chosen) containing polyplexes (N/P 12 for 
oligomers 49 and 229 or N/P 16 for oligomers 472 and 188) 24 and 48 h before 
euthanasia. Tumors and livers were harvested, immobilized in TissueTek® and cut 
into 5 µm fine sections using a cryotom (Leica CM3050 S Leica Microsystems 
GmbH, Germany). Slices were fixed with paraformaldehyde (4%), stained with 
DAPI and aster formations were documented using a fluorescence microscope 
Materials and Methods     26 
 
(Zeiss Axiovert 200, Carl Zeiss AG, Germany).  
2.7.2.3 H&E Staining 
Mice were intratumorally injected twice with Eg5-Inf7 siRNA containing 
polyplexes (N/P 16) 24 and 48 h before euthanasia. Tumors were harvested, fixed 
in formalin and embedded into paraffin. Tumors were sliced into 4.5 µm fine 
sections and stained with hematoxylin and eosin (H&E), following standard 
protocol. Results were documented using an Olympus BX41 microscope 
(Olympus, Germany).  
2.7.3 Polyplex Imaging 
For live polyplex imaging 5 x 106 Neuro2A or KB cells in a volume of 150 µl 
PBS were subcutaneously injected into the left flank (Neuro2A) or neck (KB) of 
NMRI mice. After tumors reached a volume of about 200 mm3 (10 days) 
polyplexes were injected.  
2.7.3.1 Polyplex Retention after i.t. Injection 
Near infrared (NIR) imaging was performed to display the different retention of 
intratumorally injected polyplexes (N/P 12) containing 50 µg siRNA including 
25 µg Cy7-labeled siRNA mixed in a total volume of 50 µl (HBG). Mice were 
anaesthetized with 3% isoflurane in oxygen, polyplexes were injected into the 
tumor and fluorescence was measured after 0, 0.25, 1, 4, 24, and 48 h with a CCD 
camera. After 48 h mice were sacrificed and tumors, kidneys, lungs, livers, and 
spleens were excised and fluorescence imaging was performed. All pictures were 
analyzed utilizing the IVIS Lumina system with Living Image software 3.2 
(Caliper Life Sciences, USA). For evaluation of images, efficiency of 
fluorescence signals was analyzed, after color bar scales were equalized. 
Targeted and untargeted polyplexes, containing 50 µg Cy7-labeled siRNA, or 
pure Cy7-labeled siRNA, were injected intratumorally in 50 µl HBG. NIR 
imaging was performed with a CCD camera 0, 4, 24, 48, 72, 96, and 120 h after 
polyplex injection. For evaluation of images, efficiency of fluorescence signals 
was analyzed, after color bar scales were equalized. For quantification of the 
tumor retention of the polyplexes, regions of interest (ROIs) were defined and 
total signals per ROI were calculated as total efficiency/area with Living Image 
software 3.2. The average signal intensities per group were compared over time 
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(mean ± S.E.M. of five mice per group). Pictures were taken with an exposure 
time of 5 s and medium binning.  
2.7.3.2 Polyplex Distribution after i.v. Injection 
Different untargeted polyplexes (N/P 12) containing 50 µg siRNA including 
25 µg Cy7-labeled siRNA were mixed in a total volume of 250 µl (HBG) and 
injected into the tail vein of tumor free NMRI mice. Fluorescence imaging was 
performed utilizing the IVIS Lumina system with Living Image software 3.2 
(Caliper Life Sciences, Hopkinton, MA, USA). After anesthetizing the mice with 
3% isoflurane in oxygen, polyplexes were injected into the tail vein and the 
distribution was measured after 0, 0.25, 0.5, 1, 4, and 24 h with a CCD camera. 
Experiments were performed in triplicates and pictures were analyzed using the 
Living Image software. Pictures were taken with an exposure time of 5 s and 
medium binning. 
Folate-oligomer containing targeted polyplexes with different PEG spacers (1 x, 
2 x, 3 x PEG24) or with hydrophobic modifications (tyrosine, caprylic acid, 
stearic acid) containing 50 µg Cy7-labeled siRNA, were mixed in 250 µl HBG 
and injected into the tail vein of KB tumors bearing NMRI mice. Untargeted 
polyplexes with 5 x or 8 x PEG24 chains were injected into tumor free NMRI 
mice. Each polymer was injected intravenously into three animals, with only one 
exception. The stearic acid containing polyplexes were injected once, as this 
mouse died after the application. NIR fluorescence measurement was started 
immediately after polyplex injection and repeated after 0.25, 1, 4, and 24 h 
(polyplexes with 1 x, 2 x, 3 x PEG24, tyrosine, caprylic acid or stearic acid) or 
after 0.25, 0.5, and 1 h (polyplexes with 5 x PEG24 and 8 x PEG24). For 
evaluation, the efficiency of the fluorescence signals was presented, using 
equalized color bar scales for each group. Pictures were taken with an exposure 
time of 5 s and medium binning. 
2.7.3.3 Gel Electrophoresis of Urine Samples 
Folate receptor targeted polyplexes with different PEG spacers (1 x, 3 x PEG24) 
containing 50 µg Cy7-labeled siRNA, were mixed in 250 µl HBG and injected 
intravenously into tumor free NMRI mice. The mice were injected with oligomer 
472 (n=2), 478 (n=2) polyplexes or pure siRNA (n=1). After 4 h, mice were 
anesthetized with 3% isoflurane in oxygen and placed in dorsal position. Bladders 
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were blindly punctured with an insulin syringe. Urine samples were analyzed in a 
2% (w/v) agarose gel in TBE buffer (800 mM Tris, 3.8 M boric acid, 2 mM 
EDTA) without further dilution. For staining, GelRed® was added to the liquid 
gel. Where indicated, 2 µl of a 0.5 M TCEP solution and 2 µl of a heparin solution 
were added. Gel electrophoresis was performed at 80 V for 60 min. 
2.7.4 Therapeutic Assays 
For therapeutic assays 5 x 106 Neuro2A cells in a volume of 150 µl PBS were 
subcutaneously injected into the left flank of NMRI mice.  
2.7.4.1 Dose Finding 
Two days after tumor inoculation, intratumoral treatment with polyplexes, 
containing 12.5, 25, or 50 µg Eg5 or control siRNA and oligomer 49 (N/P 12) 
mixed in a total volume of 50 µl was started. Treatment was repeated on day 4, 7, 
9, and 11. Bioluminescence signal was measured before each treatment and at day 
14 by a CCD camera (IVIS Lumina®) 15 min after peritoneal injection of 100 µl 
luciferin solution (c = 60 mg/ml). After the final measurement animals were 
sacrificed.  
2.7.4.2 siRNA Comparison 
Two days after tumor inoculation mice were separated into 4 groups (n=9) based 
on their bioluminescence signal (Caliper Life Sciences, USA). For this reason, 
bioluminescence imaging was performed using a CCD camera (IVIS Lumina®) 
and Living Image software 3.2, 15 min after intra peritoneal injection of 100 µl 
luciferin solution (c=60 mg/ml). Polyplexes consisting of oligomer 49 (N/P 12) 
either complexing Ran siRNA, Eg5 siRNA or control siRNA (50 µg/mouse) were 
mixed in a total volume of 50 µl (HBG), incubated for 60 min and injected 
intratumorally. Treatment was started at day 2 and repeated at day 4, 7, 9, 11, and 
14 (3 times per week). Tumor growth was recorded through bioluminescence 
imaging at day 4, 7, 9, 11, 14 and caliper measurement thrice a week. Mice were 
sacrificed after their tumors reached a size of 1500 mm3 (length x width2/2). 
Bioluminescence signals and tumor volumes were analyzed with GrapPad Prism® 
software. The dates when tumors reached the endpoint criteria were recorded and 
Kaplan-Maier Survival analysis was performed. 
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2.7.4.3 Oligomer Comparison 
Mice were injected with 5 × 106 Neuro2A-eGFPLuc cells subcutaneously into 
their left flank at day 0. 2 Days later the mice were separated into 6 groups (n=5) 
based on their bioluminescence signal (Caliper Life Sciences, USA). Polyplexes 
consisting of oligomers 49 (chloride salt), 386 (TFA salt in the first experiment, 
chloride salt in the second experiment), and 229 (TFA salt) (N/P 12) complexing 
either Ran or control siRNA (50 µg/mouse) in a total volume of 50 µl (HBG) 
were intratumorally injected. Treatment started at day 2 and was repeated at day 4, 
8, 11, 15 or at day 4, 8, 11, 14. Tumor growth was recorded through 
bioluminescence imaging at day 4, 8, 11, 15 or at days 4, 8, 11, 14, 16, 18. In the 
first experiment mice were sacrificed 2 days after the last treatment. In the second 
experiment mice were sacrificed when the tumor of the first mouse in the polymer 
group, Ran or control siRNA treated reached a volume of 1500 mm3 
(length x width2/2). Bioluminescence signals and tumor weights were analyzed 
with GrapPad Prism® software. 
2.8 Statistical Analysis 
Statistical analysis of all results (mean ± standard error of the mean) was 
performed using GraphPad Prism®. Statistical significance of the results was 
evaluated by one way t-test; ns = not; * p < 0.05; ** p < 0.01; *** p < 0.001.
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3 RESULTS 
3.1 Oligoamides for siRNA Delivery  
3.1.1 Design of Precise Carriers for siRNA Delivery 
Solid-phase-supported macromolecule assembly offered the possibility to 
synthesize a large library of diverse, sequence defined, synthetic oligomers133-134 
(Figure 8). Therefore, artificial Fmoc/Boc-protected amino acids with defined 1,2-
diaminoethane units were designed by D. Schaffert and N. Badgujar132. The 
diaminoethane motif in contrast to diaminopropane has unique properties as it is 
not completely protonated at physiological pH135. Diaminoethane motifs are 
protonated in the endosomes (pH 5.5) and mediate the so called “proton sponge 
effect”, responsible for the high transfection activity of polyethylenimine (PEI). 
Four artificial amino acids (Stp = Succinyl-tetraethyl-pentamine, Gtp = Glutaryl-
tetraethyl-pentamine, Ptp = Phthalyl-tetraethyl-pentamine and Gtt = Glutaryl-
triethyl-tetramine) were applied together with lysines (branching), cysteines 
(bioreversible disulfide-forming), tyrosines (stability), histidines (endosomal 
escape) and various fatty acids (stability and lysis) to generate a library of more 
than 600 defined structures by N. Badgujar, C. Dohmen, U. Lächelt, I. Martin, E. 
Salcher, D. Schaffert, C. Scholz, and C. Troiber75,133,136-137. Polycations with 
different topologies (T-shapes, i-shapes, U-shapes and branched structures) were 
synthesized to discover novel biodegradable, sequence defined siRNA carriers. 
The first two oligomer classes contain two terminal cysteines and a hydrophobic 
domain either in the middle (T-shape) or at the N terminus (i-shape). The third 
oligomer class is modified at the C and N terminus with hydrophobic domains (U-
shape) either with or without terminal cysteines. The last oligomer class contains 
three terminal cysteines for cross-linking (branched) and has no hydrophobic 
modifications. This novel approach also allowed the incorporation of shielding 
agents (for example Polyethylenglycol) and targeting ligands (for example folic 
acid, methotrexate). 
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Figure 8 Scheme of solid-phase-supported oligomer synthesis: Demonstrates the different steps during 
oligomer assembly like coupling, basic deprotection and acidic cleavage. 
3.1.2 Identification of Powerful siRNA Carriers 
To identify the requirements for successful siRNA delivery, oligomers consisting 
of different building blocks and with different topologies have been synthesized. 
Screening of these structures in a marker gene silencing screen in vitro revealed 
several structure-activity-relations75.  
Polymers containing Stp and Gtp building blocks showed the best transfection 
efficiencies in i-shape and branched structures. In contrast, the shorter Gtt 
building block was inactive in both topologies whereas the Ptp building block was 
only active in i-shaped oligomers. EtBr assays revealed Stp as the building block 
with the best binding capacity for siRNA. For branched structures and T-shapes at 
least two Stp units per arm were necessary to efficiently bind siRNA and mediate 
effective target gene knockdown. In contrast, U-shape oligomers with only one 
Stp unit were suitable for siRNA binding and mediated target gene knockdown.  
For better siRNA complexation and because of their lytic activity different fatty 
acids were incorporated into the lipo-oligomers (T-shape, i-shape and U-shape). 
Oligomers with linolic and oleic acid showed pH dependent lytic activity and 
performed best in transfection experiments compared to other fatty acids (for 
example myristic acid, stearic acid).  
Especially for branched structures, but also for T- and i-shaped oligomers 
stabilization by terminal cysteines was essential for successful siRNA 
transfection. On the contrary, U-shaped oligomers mediated efficient siRNA 
delivery without cysteines, because of the high amount of fatty acids. Serum 
challenge revealed that U-shaped oligomers with terminal cysteines form the most 
stable polyplexes, followed by U-shaped oligomers without cysteines, i-shaped 
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oligomers and branched structures.  
The different oligomer topologies mediated similar target gene knockdown in a 
murine neuroblastoma cell line (Neuro2A). On the other hand, different cell lines 
did react diversely to oligomers with different topologies. For further experiments 
three diversely shaped oligomers (49 = T-shape, 229 = i-shape, 386 = branched) 
have been chosen to demonstrate biophysical properties (siRNA binding, particle 
size) and in vitro gene silencing activity (Figure 9). U-shaped oligomers were 
excluded because they showed toxicity in a DNA transfection experiment in vivo. 
 
Figure 9 Oligomer classes: Sketches of T-shape oligomer 49 (n=2) containing 4 STP units and oleic acid, i-
shape oligomer 229 (n=3) containing 3 STP units and linolic acid and branched oligomer 386 (n=3) 
containing 9 STP units. 
3.1.2.1 Biophysical Characterization 
As described previously, effective binding of nucleic acids was a major hurdle for 
successful siRNA delivery. Different siRNA binding capacities of the three 
oligomers (49, 229, 386) were demonstrated (Figure 10). All 3 oligomers were 
able to complex the nucleic acid already at low N/P ratios. Oligomer 386 
completely bound siRNA at an N/P ratio of 3, whereas the other two carriers 
needed slightly higher oligomer amounts to completely bind siRNA.  
 
Figure 10 Gel shift assay: siRNA binding capacity of oligomers 49, 229 and 386 at different N/P ratios 
(experiment performed by C. Troiber and T. Fröhlich). 
In conclusion, the gel shift assay demonstrated the absence of free siRNA at an 
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N/P ratio of 12 for oligomers 49, 229 and 386. Therefore, this N/P was chosen for 
further characterization, like particle size and zeta potential. DLS (dynamic light 
scattering) measurement revealed very small polyplexes size for the lipo-
oligomers 49 and 229 in a range of 20-50 nm. In contrast, oligomer 386 formed 
big particles with a size of approximately 600 nm (Table 1). Zeta potential of 
oligomers 49 and 386 were medium high, whereas oligomer 229 showed only low 
zeta potential. 
Oligomer ID Oligomer sequence Z-Average (nm) Zeta potential (mV) 
49 C-Stp2-[(OleA)2-K]K-Stp2-C 23 ± 4 24.9 ± 1.0 
229 C-Stp3-C-K-(LinA)2 48 6.12 
386 [(C-Stp3)2]K-Stp3-C 597 ± 3 20.8 ± 1.3 
Table 1 Size and zeta potential measurement: Polyplex size and zeta potential at N/P 12 of 
oligomer 49, 229 and 386 (experiment performed by C. Troiber and T. Fröhlich). 
The biophysical characterization demonstrated successful siRNA binding for the 
three oligomers and the formation of polyplexes with different sizes and zeta 
potentials.  
3.1.2.2 GFP Knockdown Screen 
Target gene silencing was examined in an eGFPLus silencing assay, enabling the 
comparison of different oligomers at several N/P ratios. For this reason, cell lines 
stably expressing the marker gene eGFPLuc have been generated by lentiviral 
transduction. These cell lines were transfected with polyplexes containing either 
GFP siRNA targeting the eGFPLuc or a scrambled control siRNA. Reduced 
luciferase signals in the GFP siRNA group, two days after siRNA transfection, 
demonstrated successful target gene silencing. In contrast, reduced luciferase 
signals in both groups indicated unspecific toxicity. First knockdown experiments 
were always carried out in the Neuro2A-eGFPLuc cell line. For comparison 
reasons Neuro2A cells were transfected with “gold standard” Lipofectamine 2000 
(LF2000, standard protocol), a modified Polyethylenimine54 (PEI Succ10, w/w = 
4/1), or the novel T-shape oligomer 49 (Figure 11).   
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Figure 11 eGFPLuc silencing assay: Target gene silencing of standard polymer PEI-Succ10 and standard 
liposome LF2000 was compared to sequence defined oligomer 49 at different N/P ratios. 
Both standards and oligomer 49 were able to mediate specific target gene 
knockdown, in the GFP siRNA group, without unspecific toxicity. Oligomer 49 
showed effective target gene knockdown beginning with N/P 3 and displayed no 
toxicity even in the high N/P of 40.  
 
Figure 12 eGFPLuc silencing assay: Target gene silencing of oligomer 49 polyplexes in standard cell line 
Neuro2A was compared to HUH7 and Az521 cell lines. 
For further evaluation eGFPLuc knockdown in Neuro2A cells was compared to 
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the knockdown in human hepatocellular carcinoma cells (HUH7) and a gastric 
cancer cell line (Az521) (Figure 12). The results demonstrated the diverse 
transfection efficiency of this oligomer in different cell lines. Oligomer 49 was a 
highly effective oligomer for the transfection of Neuro2A and HUH7 cells, 
whereas the gastric cancer cell line Az521 showed unspecific toxicity after 
transfection. Thereafter, the transfection efficiencies of oligomers 49, 229 and 386 
were compared in the Neuro2A cell line (Figure 13). The results demonstrated 
similar eGFPLuc silencing mediated by the lipo-oligomers 49 and 229 and the 
branched oligomer 386.  
 
Figure 13 eGFPLuc silencing assay: Target gene silencing of oligomer 49 polyplexes was compared to 
oligomer 229 and 386 polyplexes at N/P 6 and 12. 
In conclusion, all oligomers mediated marker gene knockdown comparable to the 
standards LF2000 and PEI Succ10. The successful marker gene knockdown and 
the low toxicity of the oligomers indicated their applicability for in vivo testing. 
3.1.3 Therapeutic Gene Silencing 
Knockdown of genes involved in cell division, metabolic processes or 
angiogenesis can affect tumor progression138-140. Hence, siRNA polyplexes 
targeting genes essential for cancer cells reduce tumor cell viability and in 
consequence lead to reduced tumor growth. The previous described target genes 
Eg5 and Ran were evaluated in vitro and in an intratumoral assay in vivo for this 
purpose. Knockdown of both therapeutic targets should lead to reduced tumor cell 
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viability and tumor growth.  
3.1.3.1 Eg5 and Ran Silencing on mRNA and Protein Level  
The knockdown of therapeutic targets, Eg5 and Ran, was determined by qPCR 
(Figure 14) and Western blot analysis (Figure 15), demonstrating delivery 
efficiency and knockdown kinetics of the applied oligomers 49, 229, and 386. 
Also, the target specificity of utilized siRNA sequences was assured by these 
assays. For this purpose, Neuro2A cells were transfected with either Eg5, Ran or 
control siRNA, and cells were lysed for mRNA or protein isolation after 24, 48, 
and 72 h. Results showed effective silencing of Eg5 mRNA after 24 h for all Eg5 
siRNA containing polyplexes (Figure 14a), however with a recovery after 48 h 
(Figure 14b) and nearly no difference of Eg5 and control siRNA transfected cells 
after 72 h (Figure 14c).  
 
 
Figure 14 Gene silencing on mRNA level: qPCR data of control, Eg5 and Ran siRNA (370 nM) transfected 
cells delivered by oligomers 49, 229 and 386. GAPDH was used as housekeeper for all experiments. ∆Ct 
values of control siRNA transfected cells were set to 100% and compared to the ∆Ct values of either Eg5 or 
Ran siRNA transfected cells. Graphs (a-c) demonstrate Eg5 knockdown and (d-f) Ran knockdown after 24, 
48, and 72h 
Western blot results indicated a similar but shifted time course with a delay of one 
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day for Eg5 protein reduction. Protein knockdown at day 1 and 2 was followed by 
a recovery at day 3 (Figure 15). Efficiencies and kinetics of Ran knockdown on 
mRNA and protein level were similar to Eg5 knockdown. The main difference 
was an observed counter regulation of Ran mRNA expression (up to 150%) at 
72 h after Ran siRNA transfection (Figure 14f).  
 
Figure 15 Gene silencing on protein level: Western blot analysis of control, Eg5 and Ran siRNA (370 nM) 
transfected cells using oligomers 49, 229 and 386. GAPDH was used as loading control for all experiments. 
Western blots (a-c) demonstrate Eg5 knockdown and (d-f) demonstrate Ran knockdown after 24, 48, and 
72 h. Blots were further quantified with ImageJ software and control siRNA transfected relative intensities 
were set to 100%. 
These transfection results demonstrated the effective knockdown of Eg5 and Ran 
mRNA with minor differences in the time course, but no differences in the 
knockdown efficiency triggered by the different carriers. The branched oligomer 
386 showed the fastest kinetic, with strong protein and mRNA knockdown at day 
1 and the most persistent knockdown with significant Eg5 mRNA reduction at day 
3. Both lipo-oligomers, 49 and 229, showed comparable time courses, with 
oligomer 229 mediating slightly stronger target mRNA knockdown. These results 
demonstrated similar and efficient Eg5 and Ran knockdown on mRNA and 
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protein level. Thus they were, in accordance with our previous studies, showing 
effective eGFPLuc marker gene knockdown for the three oligomers. Further in 
vitro assays were carried out to gain a better understanding of the transfection 
efficiencies and the related biological effects.  
3.1.3.2 Cell Cycle Analysis 
Eg5 is responsible for the formation of bipolar mitotic spindles during mitosis, in 
consequence Eg5 knockdown caused cell-cycle arrest and induced apoptosis. 
Successful application of Eg5 siRNA was demonstrated by the detection of the 
typical monoastral spindles of cell nuclei in cell culture. Only dividing cells are 
affected by Eg5 knockdown, hence typical aster formation can be visualized in 
mitotic cells after DAPI (DNA) and tubulin (spindle apparatus) staining (Figure 
16).  
 
Figure 16 Aster formation assay: Eg5 knockdown by oligomer 49 polyplexes caused Aster formation in 
Neuro2A cells visualized by staining of nuclei (DAPI = blue) and tubulin (green).  
The previously successful oligomers 49 and 229 were compared in terms of their 
transfection efficiency in Neuro2A cells demonstrating successful Eg5 
knockdown for both oligomers (Figure 17). Aster formation is a positive readout 
system, therefore no mitotic figures could be observed after application of control 
siRNA.  
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Figure 17 Aster formation assay: Eg5 knockdown visualized by staining of nuclei (DAPI = blue) 
demonstrates aster formation in Neuro2A cells after transfection with polyplexes of oligomers 49 or 229. 
Control siRNA did not cause aster formation. 
Aster formation is equivalent to a mitotic block, because cells are unable to divide 
into daughter cells after Eg5 knockdown. This mitotic block led to accumulation 
of cells in G2 phase which were detectable through a flow cytometric assay. For 
this assay nuclear DNA of Eg5 and control siRNA transfected cells was stained 
with propidiumiodide (PI). Untransfected and control siRNA transfected cells 
showed typical histograms with a prominent G1-0 peak and a much smaller G2 
peak, while Eg5 transfected cells showed a diminished G1-0 peak and a much 
greater G2 peak (Figure 18). Cells between G1/G0 and G2 phase are in synthesis 
phase and were not affected by the transfection. 
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Figure 18 Cell cycle analysis by flow cytometry: Representative histograms of PI stained Neuro2A cells 
24 h after Eg5 (black) or control (light grey) siRNA transfection. The Peak at 20K demonstrates cells with 
haploid set of chromosomes (G1/G0) whereas the peak at 40K demonstrates cells with diploid set of 
chromosomes (G2). 
Again the two oligomers 49 and 229 were tested for their transfection efficiency 
in the flow cytometric assay. Significant difference between Eg5 siRNA treated 
and control siRNA treated samples was detected for both polymer formulations 
(Table 2). Although, both assays allowed the detection of successful Eg5 
knockdown in vitro, particularly the histological assay offered an interesting 
possibility for the detection of functional in vivo gene silencing. 
Polymer siRNA % of cells in 
sub G1-G0 
% of cells 
in G1-G0 
% of cells 
in S 
% of cells in 
sub G2-M 
49 
Eg5 2.4 ± 0.7 20.1 ±2.9 11.7 ± 0.2 65.8 ± 2.4 
Control 3.9 ± 0.4 57.1 ± 2.5 15.1 ± 1.1 23.6 ± 1.2 
229 
Eg5 4.4 ± 1.3 23.6 ± 8.5 14.5 ± 2.5 55.0 ± 7.8 
Control 3.3 ± 1.2 59.6 ± 0.6 14.3 ± 0.8 21.2 ± 3.3 
Table 2 Comparison of Eg5 knockdown by flow cytometry: Cell cycle stages of Neuro2A cells 24 h after 
transfection with oligomer 49 and 229 polyplexes. Cells in G1/G0, G2 and S phase were quantified after Eg5 
and control siRNA transfection.  
In a further flow cytometric assay the effects of Eg5, Ran and control siRNA, 
mediated by oligomers 49, 229 and 386 were compared to buffer treatment after 
24, 48, and 72 h (Figure 19). Altered cell cycle distribution for Eg5 and Ran 
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siRNA transfected cells was observed, while transfection with control siRNA 
showed no effect. This indicated the absence of notable unspecific oligomer 
effects.  
 
Figure 19 Effect of siRNA delivery on tumor cell cycle: Flow cytometric analysis of cell cycle distributions 
of control, Eg5 and Ran siRNA (370 nM) transfected Neuro2A cells using oligomers (a-c) 49, (d-f) 229 and 
(g-i) 386. Transfected cells were stained with propidium iodide after 24, 48, and 72 h. Eg5 and Ran siRNA 
transfected cells were compared to control siRNA and buffer (HBG) transfected cells. 
Ran knockdown caused cell death detectable through the increased sub G1/G0 
peak after 72 h (Figure 19a,d,g compared to Figure 19c,f,i), whereas Eg5 
knockdown principally led to cell cycle arrest in G2 phase (Figure 19a,d,g and 
Figure 19b,e,h) and consequently to cell death (Figure 19c,f,i). Therefore, Eg5 
knockdown could be detected by an increased G2 peak and a sub G1/G0 
population appearing 24 h after transfection (Figure 19a,d,g). The sub G1/G0 peak 
increased after 48 h (Figure 19b,e,h) and 72 h (Figure 19c,f,i), while the G2 peak 
decreased. This result indicated that transfected cells undergo cell death. In 
contrast, Ran siRNA transfected cells only showed a moderate increase of dead 
cells (sub G1/G0) after 48 and 72 h compared to control and buffer treated cells. 
The greatest effects on cell cycle were mediated by oligomer 49 (Figure 19a-c), 
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while oligomers 229 (Figure 19d-f) and 386 (Figure 19g-i) mediated the same but 
considerably reduced effects on cell cycle. This assay demonstrated that especially 
Eg5 knockdown had influence on the G2 peak, while both therapeutic siRNAs led 
to increased sub G1/G0 peaks. 
3.1.3.3 Cell Viability Assay 
A cell viability assay (by ATP measurement, CellTiter Glo) demonstrated reduced 
viability of tumor cells after Eg5 and Ran siRNA transfection. In accordance with 
previous assays, control siRNA transfected cells did not show reduced viability 
compared to buffer treated cells. Polyplexes containing either Eg5 or Ran siRNA 
decreased cell viability for the three tested oligomers.  
 
Figure 20 siRNA dependent tumor cell killing: Cell viability of Eg5, Ran and control siRNA (370 nM) 
transfected Neuro2A cells was measured 24, 48, and 72 h after transfection with oligomers (a) 49, (b) 229 and 
(c) 386. Viability of buffer treated cells was set to 100% cell viability and compared to Eg5, Ran and control 
siRNA transfected cells. 
However, differences between oligomers concerning kinetics and cell killing 
efficiency were observed (Figure 20). Oligomer 386 (Figure 20c) led to the fastest 
and strongest reduction of cell viability whereas oligomers 49 (Figure 20a) and 
229 (Figure 20b) showed slower kinetics and reduced effects on cell viability. In 
accordance with the Western blot experiments, the CellTiter Glo measurements 
confirmed the fast kinetic of oligomer 386. In summary, the in vitro assays 
demonstrated efficient siRNA delivery for all tested oligomers, as indicated by 
mRNA silencing. Furthermore, the target knockdown on mRNA and protein 
levels consequently leading to reduced tumor cell viability made the tested 
oligomers and siRNAs interesting for following in vivo experiments. 
3.1.4 Distribution of Fluorescence Labeled Polyplexes 
To determine polyplex retention after intratumoral injection or passive tumor 
targeting after intravenous injection siRNAs conjugated to fluorescent dyes were 
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incorporated into the polyplexes. Fluorescent polyplexes allowed the detection 
either in organ sections or in living animals. For imaging experiments near 
infrared dyes like Cy7 had to be applied because of the auto fluorescence of red 
blood cells and food ingredients. 
3.1.4.1 Histological Cy3 Analysis 
For the detection of successful siRNA delivery in vivo, Cy3 labeled siRNA was 
integrated into the polyplexes and injected intravenously into the tail vein of 
tumor bearing mice.  
 
Figure 21 LSM images of tumor, liver, kidney and lung cryo sections: Fluorescnece images of organ 
slices after intravenous polyplex injection were analyzed by laser-scanning-microscopy. Nuclei were stained 
with Hoechst dye (blue) and the slices were analyzed for Cy3 labeled siRNAs (red). Experiment performed 
together with Raphaela Kläger (veterinary MD thesis, LMU 2013). 
One hour after polyplex injection mice were sacrificed and tumors, livers, 
kidneys, and lungs were harvested. The tumor images confirmed that both 
polymers were able to compact siRNA, protect it from degradation in the blood 
stream and deliver siRNA into the tumors (Figure 21). LSM (laser-scanning-
microscopy) images revealed superior accumulation of Cy3 siRNA in tumors of 
oligomer 229 injected mice compared to tumors of oligomer 49 injected mice. 
Great accumulation in the liver and kidneys could be observed for both lipo-
oligomers, whereas the Cy3 signal in the lungs was very weak. Accumulation in 
the liver can be explained by the lipophilic character of the oligomers while the 
strong kidney signals are influenced by the clearance of pure siRNA or small 
particles.    
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3.1.4.2 Living Image 
For the comparison of oligomers 49, 229 and 386 after intratumoral injection, at 
first polyplex retention was assayed, because this is a crucial requirement for 
siRNA activity in vivo. Therefore, mice were injected intratumorally with 
polyplexes containing Cy7 labelled siRNA. 
 
Figure 22: Retention of siRNA in tumors. Fluorescence imaging of intratumoral injected polyplexes 
showed Cy7-siRNA signals in tumors over 48 h for all oligomers. Oligomer 386 showed increasing kidney 
signals already detectable right after injection. Experiment performed together with Raphaela Kläger 
(veterinary MD thesis, LMU 2013). 
Fluorescence signals were measured directly after polyplex injection and after 
0.25, 1, 4, 24, and 48 h (Figure 22). The images showed that all oligomers were 
able to retain siRNA in the tumors for 48 h. Oligomers 49 and 229 showed the 
best retention of siRNA with extensive Cy7 signals detectable in the tumor for 
48 h. In contrast to lipo-oligomers 49 and 229, polyplexes of oligomer 386 
showed additional early Cy7 siRNA signals in the kidneys of intratumoral 
injected mice. Cy7 signals in the tumors decreased but were still detectable after 
48 h, whereas kidney signals increased within the first 4 h and were not detectable 
after 24 and 48 h. This is consistent with renal clearance of free Cy7 siRNA after 
polyplex dissociation, analogously to the previous observation116,136. Hence, the 
Cy7 siRNA experiment demonstrated the higher stability and improved retention 
of polyplexes with the lipid-modified oligomers 49, 229 in contrast to oligomer 
386 without fatty acid modification. 
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Figure 23 Cy7 signals in mouse organs: Fluorescence imaging of i.t. injected polyplexes showed Cy7-
siRNA signals in tumors after 48 h for all oligomers. Oligomer 49 showed Cy7 signals detectable in the liver. 
Experiment performed together with Raphaela Kläger (veterinary MD thesis, LMU 2013). 
The results were confirmed by measuring the harvested organs after euthanasia of 
the mice (Figure 23). Only tumors showed measurable Cy7 signals and the lipo-
oligomer 49 and 229 showed stronger tumor signals than the branched oligomer 
386. 
3.1.5 Dose Escalation Study 
A dose response experiment was performed to determine the siRNA dose 
necessary for successful tumor growth reduction after intratumoral polyplex 
injection. For this experiment oligomer 49 was chosen and injected in an N/P of 
12 for all siRNA concentrations. Hence, 12.5, 25, or 50 µg Eg5 siRNA or control 
siRNA containing polyplexes were injected into subcutaneous Neuro2A-eGFPLuc 
tumors. Successful delivery of Eg5 siRNA has been previously demonstrated to 
result in cell cycle arrest and apoptosis of tumor cells. Therefore, successful Eg5 
knockdown slowed down tumor progression. The subcutaneous tumors were 
treated five times starting with day 2 (2, 4, 7, 9, 11) after tumor cell inoculation 
and the bioluminescent tumor signals were measured at indicated time points 
(Figure 24).  
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Figure 24 Dose escalation experiment: Tumor growth of subcutaneous Neuro2A-eGFPLuc tumors in mice 
after repeated intratumoral treatment (3 mice per group) with oligomer 49 and Eg5 or control siRNA (N/P 12) 
polyplexes. Animals were treated with 50 µg, 25 µg, or 12.5 µg siRNA per mouse at day 2, 4, 7, 9 and 11 
after tumor cell inoculation. The treatment group with 12.5 µg siRNA was terminated on day 11 due to 
excessive tumor size. Experiment performed together with Raphaela Kläger (veterinary MD thesis, LMU 
2013). 
Experiments had to be terminated on day 11 and 14, respectively, because of 
excessive tumor growth in the control groups. With a concentration of 12.5 µg 
siRNA, no positive effect of the Eg5 siRNA on tumor growth could be observed 
after 11 days. In contrast, 25 µg Eg5 siRNA per treatment slightly reduced tumor 
growth, but a relatively large variation within the treatment group was observed. 
Best results were achieved with 50 µg Eg5 siRNA per treatment resulting in 
significantly reduced tumor growth compared to control siRNA.  
 
Figure 25 Bioluminescence images of Neuro2A-eGFPLuc tumors: Polyplex treatment resulted in reduced 
tumor growth compared to buffer treatment. The Eg5 polyplexes mediated siRNA specific tumor growth 
reduction in contrast to control siRNA polyplexes. Experiment performed together with Raphaela Kläger 
(veterinary MD thesis, LMU 2013). 
The bioluminescence images demonstrated the dose dependency of tumor growth 
reduction mediated by Eg5 polyplexes (Figure 25). This experiment helped to 
determine the minimal siRNA doses per injection and demonstrated the ability of 
this new class of oligomers to deliver siRNA in vivo upon intratumoral injection. 
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3.1.6 Evaluation of Therapeutic siRNAs 
After the required dose for an intratumoral treatment had been defined, the effects 
of Eg5 and Ran siRNA on tumor growth were compared. Two days after 
implantation of Neuro2A-eGFPLuc cells, mice were imaged detecting the 
bioluminescence signals of implanted tumor cells. According to this, mice were 
divided into four groups receiving either buffer or siRNA polyplexes. Polyplexes 
consisting of oligomer 49 complexing either Eg5-, Ran- or control siRNA were 
injected directly into the tumor. The treatment was started at day 2 and repeated at 
days 4, 7, 9, 11, and 14.  
 
Figure 26 siRNA comparison after intratumoral treatment: Intratumoral injection of oligomer 49 
polyplexes for the treatment of subcutaneous Neuro2A-eGFPLuc tumors. Polyplexes were injected thrice 
weekly and in total 6 times. Left figure shows bioluminescence imaging of the subcutaneous tumors. Eg5 and 
Ran siRNA treated tumors showed significantly reduced bioluminescence starting with day 9 compared to 
control siRNA transfected tumors (Eg5: day 9*, day 11**, day 14**; Ran day 9*, day 11**, day 14***). 
Right figure shows the reduced tumor volumes of Eg5 and Ran siRNA transfected tumors compared to 
control siRNA transfection (Eg5: day 11*, day 14**, day 16***, day 18***; Ran day 11**, day 14**, day 
16***, day 18***). Experiment performed together with Raphaela Kläger (veterinary MD thesis, LMU 
2013). 
During the treatment period, tumor growth was detected by bioluminescence 
imaging (Figure 26). Altered bioluminescence signals concerning the different 
treatments could be detected starting with day 9. All polyplex treated mice 
showed reduced luciferase signals compared to buffer treated mice. However, Eg5 
and Ran siRNA treatment resulted in far more reduced bioluminescence signals 
than control siRNA treatment. From day 9 on, tumor growth was also determined 
by calliper measurement controlling the experimental endpoint criteria of 
1500 mm3 tumor volume (Figure 26). Mice were sacrificed, when tumors 
exceeded a volume of 1500 mm3 and dates were recorded enabling Kaplan-Maier 
survival analysis (Figure 27). The most significant reduction of tumor volume was 
mediated by Ran siRNA followed by Eg5 siRNA, whereas control siRNA and 
buffer treatment were far less effective (Figure 26a,b). Consequently, survival of 
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Ran and Eg5 siRNA treated groups was significantly prolonged compared to 
control siRNA and buffer treated groups.  
 
Figure 27 Kaplan Maier survival analysis: After the treatment interval tumors were allowed to grow until 
they reached a volume of 1500 mm3, then mice were sacrificed and Kaplan-Maier survival analysis was 
performed (Mean survival: HBG 18 d; control siRNA 20,5 d; Eg5 siRNA 25 d; Ran siRNA 28 d). 
Experiment performed together with Raphaela Kläger (veterinary MD thesis, LMU 2013). 
Mean survival after 6 intratumoral treatments with Ran siRNA was 28 days 
compared to Eg5 siRNA with 25 days, control siRNA with 20.5 days and buffer 
with 18 days (Figure 27). To exclude unspecific effects of oligomer 49, tumor 
growth reduction of Ran and Eg5 siRNA treated mice was always compared to 
control siRNA treatment. The reduced bioluminescence signals and tumor sizes, 
as well as a prolonged survival of Ran and Eg5 treated mice provided significant 
evidence of the positive in vivo effect of both therapeutic siRNAs.  
 
Figure 28 Aster formation assay in vivo: Intratumoral injection of oligomer 49 Eg5 siRNA polyplexes 
showed aster formation and confirmed Eg5 knockdown in Neuro2A tumor cells. Cryo sections were stained 
with Hoechst dye (blue) and analyzed with a fluorescence microscope. Experiment performed together with 
Raphaela Kläger (veterinary MD thesis, LMU 2013). 
Additionally, mitotic arrest by Eg5 siRNA indicated successful in vivo target gene 
silencing (Figure 28). Tumors were excised 24 h after polyplex injection and 5 µm 
fine sections were cut. After Hoechst staining aster formation was only detected in 
Eg5 siRNA treated tumors, in accordance with the previous in vitro results. Ran 
knockdown was demonstrated with a TUNEL assay, for the detection of apoptotic 
cells (Figure 29). This assay allowed the binding of fluorescent labelled 
nucleotides to the free 3´ends of DNA fragmented during apoptosis. Tumors 
treated with Ran siRNA polyplexes showed positive TUNEL staining in contrast 
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to control siRNA treated tumors. 
 
Figure 29 TUNEL assay for the detection of apoptotic cells: Intratumoral injection of oligomer 49 Ran 
siRNA polyplexes showed positive tunnel staining and confirmed that Ran knockdown led to apoptosis of 
Neuro2A tumor cells. Experiment performed together with Raphaela Kläger (veterinary MD thesis, LMU 
2013). 
Ran siRNA was chosen for subsequent experiments, as treated tumors showed the 
lowest bioluminescence signals, the smallest tumor volumes and the most 
extended survival. 
3.1.7 Comparison of Different siRNA Carriers 
Next, the three oligomers were evaluated using Ran siRNA polyplexes for 
intratumoral treatment as described before. Accordingly, mice were grouped 
based on their bioluminescence signal 2 days after the implantation of Neuro2A-
eGFPLuc cells and the intratumoral treatment with Ran or control siRNA was 
started. siRNA polyplexes consisting of oligomers 49, 229 and 386 were injected 
directly into the tumors. The injection interval was changed to only two injections 
per week compared to three injections per week in the previous study. Tumor 
progression was measured by bioluminescence imaging. Bioluminescence signals 
were detected at day 4, 8, 11, and 15 enabling the comparison of Ran and control 
siRNA treated groups. All animals were sacrificed two days after the last 
treatment and tumors were excised to compare tumor weights of the different 
groups. Despite the less frequent treatment regime, the previously tested oligomer 
49 still mediated a measurable antitumoral effect in the Ran siRNA treated group 
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(Figure 30b), which was confirmed comparing the tumor weights of Ran and 
control siRNA treated groups (Figure 30a). The i-shape oligomer 229 failed to 
mediate any positive effect on tumor growth for Ran siRNA treated animals 
(Figure 30c). In contrast, the branched oligomer 386 showed a great reduction of 
the bioluminescence signal and also a significant effect on tumor weight for the 
Ran siRNA treated mice (Figure 30d).  
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Figure 30 Comparison of different oligomer polyplexes in antitumoral efficacy: Intratumoral injection of 
oligomer 49, 229 and 386 containing polyplexes (50 µg siRNA per animal; N/P 12) for the treatment of 
Neuro2A-eGFPLuc tumors. Polyplexes containing either Ran or control siRNA were injected twice weekly in 
total 5 times.  (a) At 2 days after the last treatment mice were sacrificed and tumor weights were analyzed to 
compare the tumors of control and RAN siRNA treated mice. (b-d) show tumor bioluminescence counts of 
Ran and control siRNA treated mice with the (b) 49, (c) 229 and (d) 386 oligomer formulations.  (e) 
Intratumoral injection of oligomer 49 and 386 containing polyplexes for the treatment of Neuro2A-eGFPLuc 
tumors as described above. After the treatment period tumors were allowed to grow until one tumor in the 
oligomer groups reached a volume of 1500 mm3 (day 18 for 49, day 18 for 386). Mice were sacrificed and 
tumor weights were analyzed to compare the tumors of control and Ran siRNA treated mice. (f) Shows 
bioluminescence tumor counts of siRNA/386 polyplex treated mice. Experiment performed together with 
Raphaela Kläger (veterinary MD thesis, LMU 2013). 
This experiment allowed the separation of the oligomers which were all effective 
in vitro, into a clear in vivo efficiency order. In this first in vivo oligomer 
comparison all mice were sacrificed 2 days after the last treatment. Oligomers 229 
and 386 were used as trifluoroacetic acid (TFA) salts instead of chloride salt. 
Apparently TFA mediated some unspecific antitumoral toxicity, therefore in a 
second experiment only chloride salts of the previously active oligomers 49 and 
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386 were applied to allow better comparability between the oligomers. Mice were 
sacrificed at day 18 when the first mouse in the oligomer group reached a tumor 
volume of 1500 mm3. Tumors were excised to compare tumor weights of Ran 
siRNA and control siRNA treated mice. In conclusion, tumor weights and 
bioluminescence signals revealed significant tumor growth reduction in the Ran 
siRNA group of oligomer 386 (Figure 30e,f) in both experiments. In contrast, 
oligomer 49 showed borderline efficiency when injected twice a week, with 
significant effects on tumor weights in the first but without significant effects in 
the second experiment (Figure 30e, bioluminescence data not shown).  
3.1.8 Oligoamides with Enhanced Stability 
High stability is an important requirement for the in vivo administration of 
polyplexes. Particularly after intravenous injections, polyplexes interact with 
serum proteins and blood cells leading to dissociation of the particles141. 
Therefore, precise changes in the oligomer structure affecting size, charge and 
stability of the polyplexes can positively influence in vivo gene silencing. For this 
reason C. Troiber included tyrosine-trimers into the T-shaped structures replacing 
terminal cysteines, central fatty acids or in addition to terminal cysteines to 
enhance polyplex stability142. The new polyplexes were investigated according to 
biophysical properties, transfection efficiency, in vivo distribution upon 
intravenous injection and in vivo transfection efficiency after intratumoral 
injection.  
3.1.8.1 Biophysical Characterization 
Agarose gel shift assays were performed to demonstrate siRNA binding capacity 
of oligotyrosine containing polyplexes. Control oligomers 216 with only central 
fatty acids for stabilization and 468 with central oligotyrosines and terminal 
cysteines showed reduced siRNA binding capacity compared to standard oligomer 
49. In contrast, replacement of terminal cysteines by oligotyrosines (332) or the 
substitution of terminal cysteines and central fatty acids by oligotyrosines (333) 
displayed siRNA binding properties analogous to oligomer 49. This demonstrated 
that terminal oligotyrosines can substitute the stabilizing activity of either terminal 
cysteines or central fatty acids. Combination of terminal oligotyrosines and 
cysteines (454, 464) independent of their central modification improved siRNA 
binding compared to oligomer 49. Gel shift assays demonstrated the increased 
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stability of oligomers with compared to oligomers without additional 
oligotyrosines (Figure 31). 
 
Figure 31 Gelshift assay: siRNA binding capacity of oligomers at different N/P ratios was tested in 2% 
agarose gels (experiment performed by C. Troiber). 
For further characterization, particle size and zeta potential of the polyplexes were 
analyzed by DLS measurement (Table 3). Oligomer 468 polyplexes with solely 
central oligotyrosines could not be analyzed as no signal was measurable, whereas 
the sizes of all other siRNA polyplexes at N/P 12 was in a range applicable for 
further in vivo evaluations.  
Oligomer ID Oligomer sequence Z-average (nm) Zeta potential (mV) 
216 A-Stp2-[(OleA)2-K]-Stp2-A 32 ± 2 5.1 ± 0.3 
49 C-Stp2-[(OleA)2-K]-Stp2-C 23 ± 4 24.9 ± 1.0 
332 Y3-Stp2-[(OleA)2-K]-Stp2-Y3 150 ± 2 38.1 ± 0.8 
454 C-Y3-Stp2-[(OleA)2-K]-Stp2-Y3-C 99 ± 2 50.7 ± 0.8 
468 C-Stp2-[(Y3)2-K]-Stp2-C n.d.* n.d.* 
333 Y3-Stp2-[(Y3)2-K]-Stp2-Y3 334 ± 46 16.7 ± 0.3 
464 C-Y3-Stp2-[(Y3)2-K]-Stp2-Y3-C 243 ± 12 13.3 ± 0.4 
Table 3 Size and zeta potential measurement: Polyplex size and zeta potential of different 
oligomer at N/P 12 was determined by DLS measurement (experiment performed by C. Troiber). 
Simulating in vivo conditions, the polyplexes were analyzed for their stability in 
fetal calf serum (FCS). Therefore, polyplexes were formed in Hepes buffer, 
followed by the addition of FCS. The samples were incubated at 37°C for 0, 10, 
30, and 90 min. Afterwards, gel electrophoresis was performed to investigate 
whether the polyplexes were stable, partially stable, or instable. Moreover, 
polyplexes were treated with 50 I.U. of heparin per sample after 90 min in order 
to dissociate polyplexes, and to investigate if the siRNA was degraded by serum 
proteins. 
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Figure 32 Polyplex stability: Agarose gel shift assay demonstrate siRNA binding and release after addition 
of 90% FCS for several tyrosine modified oligomers at N/P 12. Polyplexes were incubated for 0, 10, 30, or 
90 min with FCS and afterwards analyzed by gel electrophoresis. For control reasons samples incubated for 
90 min in FCS were treated with heparin to dissociate the polyplex and visualize free siRNA (experiment 
performed by C. Troiber). 
The siRNA band of heparin treated samples was comparable to free siRNA at all 
points in time. Hence, no degradation of the complexed or free siRNA occurred 
during the incubation time. This is not unexpected as 2´methoxy stabilized siRNA 
was applied in the experiments. After gel electrophoresis, no siRNA migration 
was observable for 454 and 464 polyplexes, confirming the serum stability of 
these polyplexes (Figure 32). In contrast, 332 and 49 polyplexes dissociated 
partially at 37°C after 90 min, as a band at the free siRNA level appeared. The 
remaining oligomer polyplexes were instable in serum and free siRNA was 
detected immediately after addition of serum. This data showed that a 
combination of oligotyrosines and cysteines at the ends of our oligomers led to a 
favorable stabilization and improved resistance to serum protein mediated 
disassembly. The different polyplex stability was confirmed by C. Troiber through 
fluorescence correlation spectroscopy measurements136. 
3.1.8.2 GFP Knockdown Screen 
Target gene silencing of the stabilized polyplexes was examined in the previously 
described eGFPLuc marker gene assay. Oligomers 216 and 333 demonstrating 
low stability against FCS were also ineffective mediating eGFPLuc knockdown. 
In contrast, all other oligomers successfully mediated target gene silencing 
(Figure 33). The addition of terminal oligotyrosines was a favorable modification 
(oligomers 454 and 464) leading to stronger target gene knockdown compared to 
oligomer 49. In contrast, the alteration of the central domain (fatty acid 454, 
oligotyrosine 464) showed only moderate influence on the transfection efficiency. 
This experiment demonstrated that polyplex stability directly correlated with 
eGFPLuc knockdown in vitro. 
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Figure 33 eGFPLuc silencing assay: Target gene silencing of different unmodified and tyrosine modified 
polyplexes at N/P 6 and 12. Gene silencing of the novel oligomers was compared to standard oligomer 49.  
In summary, the class of oligotyrosine containing oligomers was efficient in 
siRNA transfection. Replacement of terminal cysteines by tyrosines generated 
oligomers with equal transfection efficiency to standard oligomer 49, whereas the 
addition of terminal oligotyrosines created carriers superior to standard oligomer 
49. 
3.1.8.3 Distribution of Fluorescence Labeled Polyplexes 
Polyplex distribution after systemic administration was evaluated through NIR 
fluorescence imaging. Pure Cy7 labeled siRNA revealed a short circulation time 
followed by fast renal clearance comparable to oligomer 216 polyplexes (Figure 
34). Renal clearence was possible for pure siRNA but not for polyplexes with a 
size above 30 nm. Therefore, Cy7 signals detectable in the kidneys and bladder of 
oligomer 216 polyplexes are caused by free siRNA after polyplex degradation in 
the blood stream.  
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Figure 34 Fluorescence imaging: Images of a representative mouse (n=3) demonstrating distribution of Cy7 
labeled siRNA or Cy7 labeled siRNA complexed with oligomer 216  in ventral (upper row) and dorsal (lower 
row) position. The efficiencies were recorded and all images were adjusted to same maxima and minima. 
Experiment performed together with Annika Hermann (veterinary MD thesis, LMU). 
In contrast, to oligomer 216 all other oligomers are able to complex siRNA more 
stably leading to longer circulation times for the polyplexes. The lipophilic 
character of the oligomers caused liver accumulation for oligomer 49 and 332 
polyplexes after intravenous injection. Replacing the terminal cysteines (49) by 
tyrosines (332) increased circulation times and liver accumulation (Figure 35).    
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Figure 35 Fluorescence imaging: Images of a representative mouse (n=3) demonstrating distribution of Cy7 
labeled siRNA complexed with oligomer 49 and 332 in ventral (upper row) and dorsal (lower row) position. 
The efficiencies were recorded and all images were adjusted to same maxima and minima. Experiment 
performed together with Annika Hermann (veterinary MD thesis, LMU). 
Oligomer 454 confirmed the previously described high stability and showed long 
circulation times (Figure 36). Cy7 signals were still detectable in the bloodstream 
4 h after polyplex injection demonstrating the presence of stable circulating 
polyplexes. Oligomer 468 polyplexes were not detectable in the circulation, 
because the fluorescence signal was quenched due to the strong compaction of the 
labeled siRNA.     
Results     58 
 
 
Figure 36 Fluorescence imaging: Images of a representative mouse (n=3) demonstrating distribution of Cy7 
labeled siRNA complexed with oligomer 454 and 468 in ventral (upper row) and dorsal (lower row) position. 
The efficiencies were recorded and all images were adjusted to same maxima and minima. Experiment 
performed together with Annika Hermann (veterinary MD thesis, LMU). 
Oligomer 333 initially displayed good systemic tissue distribution, whereas after 
4 h only a high signal in the kidneys and the bladder was detected (Figure 37). 
Polyplexes of oligomers 464 also showed a strong quenching of the fluorescent 
Cy7 signal upon polyplex formation and hampered monitoring of polyplex 
distribution by NIR imaging. 
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Figure 37 Fluorescence imaging: Images of a representative mouse (n=3) demonstrating distribution of Cy7 
labeled siRNA complexed with oligomer 333 and 464 in ventral (upper row) and dorsal (lower row) position. 
The efficiencies were recorded and all images were adjusted to same maxima and minima. Experiment 
performed together with Annika Hermann (veterinary MD thesis, LMU). 
Excluding the non detectable oligomers, polyplexes of oligomers 49, 332, and 454 
initially displayed good systemic distribution. Shortly after polyplex injection, a 
liver signal was observed in dorsal position due to the lipophilic character of the 
oligomers. The 454 and 332 polyplexes showed the most beneficial distribution, 
followed by 49 polyplexes. This experiment proved the favorable characteristic of 
oligotyrosine modified polyplexes.  
3.1.8.4 Oligomer Screen 
Consequently, the polyplexes of oligomers 49 (control), 332, 454, 464 and 468 
were investigated for their therapeutic potential after intratumoral injection. 
According to the previous described intratumoral treatment, polyplexes containing 
either Ran or control siRNA were injected. Tumor growth of subcutaneously 
implanted Neuro2A-eGFPLuc tumors was again monitored by bioluminescence 
imaging (Figure 38). This time control oligomer 49 failed to reduce tumor growth 
in the Ran siRNA treated group compared to the control siRNA group. In 
contrast, mice treated with oligomers 332 and 468 Ran siRNA polyplexes showed 
Results     60 
 
reduced tumor growth compared to control siRNA treated mice. Only these two 
polyplexes were able to selectively reduce tumor volume and tumor weight in the 
Ran siRNA group, whereas mice treated with other polyplexes formulations could 
not reduce tumor growth. 
 
Figure 38 Bioluminescence signals and tumor weights of polyplex treated tumors: Bioluminescence 
imaging of subcutaneously implanted Neuro2A tumors after treatment with several T-shaped oligomer 
polyplexes either containing Ran siRNA or control siRNA. Mice were sacrificed when one mouse in the 
polymer group reached a tumor volume 1500 mm3 and tumor weights of the two groups were recorded. 
Experiment performed together with Raphaela Kläger (veterinary MD thesis, LMU 2013) and Annika 
Hermann (veterinary MD thesis, LMU). 
Contrary effects in the groups treated with oligomer 464 can be explained due to 
the strong necrotic effects caused by these polyplexes. Hence, the antitumoral 
effects in this group were mediated by the toxicity of the polyplexes and not by 
target gene knockdown. Oligomer 454 showed some effects on tumor growth in 
the Ran siRNA group between day 10 and day 15, but in conclusion 
bioluminescence signals and tumor weights were on the same level in both siRNA 
groups. In summary, oligomers 332 and 468 and in the previous study oligomer 
386 and 49 mediated tumor growth reduction in the Ran siRNA group. These 
results indicated that highly stable polyplexes were not suitable for intratumoral 
applications, in particular the less stable polyplexes showed good tumor reduction 
in the Ran siRNA group. After the evaluation of 7 oligomers and the exclusion of 
oligomer 464 because of necrotic effects this intratumoral assay allowed the 
classification of 6 in vitro effective oligomers into an in vivo effectivity order:       
229<454<49<468<332<386. Again polyplex stability was not the most important 
factor for successful gene silencing after intratumoral injection.  
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3.2 Targeted Oligoamides for siRNA Delivery 
3.2.1 Folic Acid Linked Targeting Oligomers  
Targeted structures were synthesized by solid-phase-supported peptide synthesis 
as afore described. C. Dohmen generated a cationic backbone consisting of two 
arms each with 4 STP units, terminal cysteines, and one central lysine (Figure 39). 
Monodisperse polyethylene glycol (PEG) was coupled to the central lysine, 
followed by region-selective coupling of folic acid as ligand for specific cell 
targeting. For control experiments alanine instead of folic acid was coupled to the 
monodisperse PEG. For the generation of a structure library different fatty acids 
(caprylic acid, stearic acid) and tyrosine-trimers were incorporated into the 
structures to increase polyplex size and stability. Also, extended PEG chains (2 x-, 
3 x-, 5 x-, 8 x 24 monomers) were introduced to increase polyplex size.   
To increase the low endosomal escape ability particularly of carriers without fatty 
acid modification, the endosomolytic peptide Inf7 was coupled to the 5’-end of 
the siRNA sense strand by C. Dohmen (LMU, PhD thesis 2012). On the contrary 
to conventional delivery systems, the current design enabled the separation of 
requirements for successful siRNA delivery between carrier and siRNA. In the 
novel delivery system the oligomeric carrier was responsible for the binding of 
nucleic acids and specific transport to the target cell, whereas the siRNA provided 
the endosomal escape domain. C. Dohmen showed the efficient synthesis and 
purification of these molecules, including a qualitative and quantitative analysis of 
the products. 
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Figure 39 Chemical structures of the oligomer backbone and folic acid: Upper structure shows the 
backbone of standard oligomer 356 with n = 4 and x = 1. Folic acid is coupled via the γ-carboxy group 
indicated by the arrow. 
3.2.1.1 Biophysical Characterization 
Successful siRNA binding by the carrier was demonstrated through gel shift 
assays. The assays demonstrated siRNA binding of the standard structure (356) 
starting with N/P 3 and nearly complete siRNA binding at N/P 20 (Figure 40). 
This siRNA binding capacity was lower than for the previously described 
oligomers. Therefore, N/P 16 was chosen for further characterizations. 
Incorporation of longer PEG chains (maximum 8 x more than oligomer 356) 
reduced nucleic acid complexation detectable by reduced siRNA retardation in the 
gel shift assay.  
 
Figure 40 Gel shift assay: Targeted oligomer 356 demonstrating efficient siRNA binding at high N/P ratios. 
Oligomer 647 with maximal prolonged PEG chain showed low binding efficiency (experiment performed by 
C. Dohmen) 
The necessity of terminal cysteines for successful siRNA binding was previously 
demonstrated by T. Fröhlich (PhD thesis 2012) comparing oligomer 356 with and 
Results     63 
 
oligomer 420 without terminal cysteines.  
Size of the nanoparticles and pure siRNA was measured by fluorescence 
correlation spectroscopy (C. Troiber, C. Dohmen and D. Edinger).  Standard 
oligomer 356 formed nanoparticles with a hydrodynamic diameter of only 5.8 nm, 
only 1.4-fold larger than free siRNA with 4.2 nm hydrodynamic diameter (Table 
4). Prolonged PEG spacer resulted in nanoparticles with a maximal size of 
50.8 nm hydrodynamic diameter. Increasing sizes of oligomers 482 < 483 < 646 
can be explained due to the prolonged PEG spacers. In contrast, the strongly 
increased size of oligomer 647 was caused by the looser particle formation also 
demonstrated in the gel shift experiment. Modification with tyrosines did not 
influence particle size whereas the incorporation of fatty acids led to structures 
with highly increased hydrodynamic diameters. 
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Oligomer ID Oligomer sequence rh (nm) 
 
siRNA 2.1 ± 0.1 
356 Fol-PEG24-K(Stp4-C)2 3.0 ± 0.1 
482 Fol-PEG48-K(Stp4-C)2 3.2 ± 0.1 
483 Fol-PEG72-K(Stp4-C)2 4.4 ± 0.1 
646 Fol-PEG120-K(Stp4-C)2 5.8 ± 0.2 
647 Fol-PEG192-K(Stp4-C)2 25.4 ± 0.9 
484 Fol-PEG24-K(Stp4-Y3-C)2 2.8 ± 0.2 
481 Fol-PEG24-K[Stp4-K(K-CapA2)C]2 16.9 ± 0.2 
480 Fol-PEG24-K[Stp4-K(K-SteA2)C]2 160.3 ± 0.6 
Table 4 Particle size measurement by FCS: Fluorescence correlation spectroscopy revealed the 
hydrodynamic radius for folic acid targeted oligomers. (Experiments performed by C. Troiber) 
DLS measurements demonstrated an overall zeta potential of 0 mV (± 3 mV) for 
PEGylated siRNA nanoparticles whereas the same polyplexes lacking the PEG 
shielding showed significantly higher zeta potential between 10 and 15 mV 
(experiments performed by C. Dohmen). Low zeta potential is favorable for in 
vivo application because it inhibits interactions with cell surfaces and blood 
proteins (22, 23) through electrostatic interactions. To enable efficient cellular 
uptake, folic acid was covalently attached to the PEG shield. As this ligand has a 
very high binding affinity to its receptor, (24-25) it should selectively mediate cell 
attachment and endocytosis into its target cell.  
3.2.1.2 Folic Acid Receptor Levels in Different Cell Lines 
Before transfection experiments could be conducted cell lines expressing the folic 
acid receptor had to be determined. For this reason several cell lines were 
screened for their receptor status (Figure 41). In this screen only the ovarian 
carcinoma (IGROV) and the cervical carcinoma (KB derived from HeLa cells) 
cell lines showed high folic acid receptor status.  
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Figure 41 Folic acid receptor status of several cell lines: Flow cytometry experiments were performed to 
quantify the membrane bound folic acid receptor status after antibody staining.  
For this reason KB cells stably expressing the eGFPLuc plasmid were generated 
and used as standard cell line for transfection experiments with folic acid targeted 
nanocarriers. 
3.2.1.3 Uptake Studies in KB and IGROV Cells 
To verify the receptor mediated uptake, polyplexes were formed with Cy5 label 
siRNA. Transfection of KB cells, with folic acid targeted and untargeted 
nanoparticles, revealed increased uptake solely for targeted nanocarriers by flow 
cytometric analysis. Competition with an excess of free folic acid or the use of 
Neuro2A cells with a low folic acid receptor level, led to a strongly reduced 
cellular association. In summary, the requirement of targeting ligands for 
successful siRNA uptake and the receptor selective uptake was demonstrated by 
T. Fröhlich. Further experiments using folic acid receptor expressing KB and 
IGROV cells confirmed polyplex uptake with Cy3 containing siRNA polyplexes. 
Histological analysis of these pictures revealed high numbers of Cy3 positive cells 
in both cell lines after 45 min incubation time (Figure 42). 
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Figure 42 Histological analysis of polyplex uptake: KB and IGROV cells were transfected with Cy3 
siRNA containing polyplexes. Nuclei were stained with Hoechst (blue) to analyze Cy3 (red) positive cells by 
fluorescence microscopy.  
The results confirmed the flow cytometry studies performed by T. Fröhlich and 
showed efficient polyplex uptake after short incubation time. 
3.2.1.4 GFP and Eg5 Knockdown Studies in vitro 
KB cells stably expressing the eGFPLuc plasmid were used as a reporter system 
for marker gene silencing studies. To demonstrate the importance of every single 
component controls lacking the folic acid ligand, the endosomolytic peptide or 
incorporating control siRNA sequences were used.  
 
Figure 43 eGFPLuc silencing experiments: KB eGFPLuc cells were transfected with folic acid targeted 
(356) and untargeted (188) oligomers. GFP and control siRNAs modified with the lytic peptide Inf7 or 
without Inf7 modification were used to demonstrate siRNA specific silencing and the necessity of the lytic 
peptide Inf7.   
Standard polymer PEI-Succ10 demonstrated poor transfection efficiency on KB 
cells with unspecific eGFPLuc silencing in the control siRNA group (Figure 43). 
In contrast, the targeting oligomers demonstrated efficient target gene knockdown 
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with Inf7 modified siRNA in all tested ratios. Unmodified siRNAs required higher 
N/P ratios, for successful endosomal escape and efficient target gene knockdown. 
This finding was consistent with the postulated poor endosomal escape efficiency 
of the nanocarriers. Polyplexes incorporating control siRNA with and without 
Inf7 modification could not show any knockdown effect, demonstrating the 
absence of unwanted side effects. Untargeted oligomers only showed moderate 
target gene knockdown at high N/P ratios with Inf7 modified GFP siRNA, 
whereas all other untargeted groups did not show silencing effects. The results 
clearly showed the high transfection efficiency of the novel delivery system while 
all mentioned controls showed reduced or no silencing efficiency under the 
transfection conditions employed. 
 
Figure 44 Comparison of eGFP-Luc knockdown: Shows the transfection results of KB-eGFPLuc cells 
with targeted (356) oligomers compared to the gold standard LF2000 using  GFP and control siRNAs 
modified with the lytic peptide Inf7 or without Inf7 modification.   
Furthermore, transfection efficiency of the novel delivery system was compared 
to the efficiency of the gold standard (LF2000). Again the KB cells showed high 
sensitivity towards transfection reagents demonstrated by the unspecific reduction 
in the control siRNA group transfected with LF2000. GFP silencing was reduced 
compared to the novel carrier system because of the high toxicity of LF2000 
lipoplexes after 4 h incubation time (Figure 44). Reducing the incubation time to 
30 min reduced the cytotoxicity but also the knockdown efficiency of LF2000 
lipoplexes. In summary, the novel nanocarrier mediated improved silencing with 
reduced cytotoxicity compared to the gold standard for transfection experiments.  
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Figure 45 Titration of siRNA concentrations: In the upper row the amounts of oligomer and siRNA were 
reduced accordingly, whereas in the lower row only the amounts of siRNA were reduced.  
For previous transfection experiments relatively high amounts of siRNA (200 nM) 
were used. Hence, titration experiments were performed to examine the critical 
oligomer and siRNA concentrations for successful gene silencing (Figure 45). In a 
first experiment N/P ratios were kept constant for all siRNA ratios and the diverse 
polyplexes were incubated for 48 h on the cells. Targeted oligomer in 
combination with lytic GFP siRNA mediated about 50% target gene knockdown 
down to a siRNA concentration of 25 nM for N/P 20. Decreasing knockdown 
efficiencies for N/P 12 and 6 demonstrate the importance of critical oligomer 
amounts. Subsequently knockdown experiments were performed with constant 
amounts of oligomer for all siRNA ratios (increasing N/P ratios) and the diverse 
polyplexes were incubated for 45 min on the cells. The highest oligomer 
concentration with N/P 20 for siRNA concentrations of 200 nM demonstrated 
good GFP silencing down to siRNA concentrations of 6 nM. Medium oligomer 
concentrations were also effective down to siRNA concentrations of 6 nM, 
whereas the lowest oligomer concentration was only effective for the highest 
siRNA concentration. These experiments demonstrated the importance of critical 
oligomer concentration, whereas only very low siRNA concentrations are required 
for successful target gene knockdown.  
For further characterization a second target was selected. Again Eg5 silencing was 
chosen enabling the analysis of mitotic cell arrest and characteristic aster 
formation. In accordance with the eGFPLuc silencing experiments, only KB cells 
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transfected with folic acid targeted carrier 356 demonstrated aster formations. 
Untargeted nanocarriers could not mediate target gene silencing because of the 
short incubation time of 45 min. After DAPI staining the microscopic pictures 
showed the characteristic aster formation only in the Eg5 siRNA group, 
demonstrating the effectiveness of this positive read out system (Figure 46). 
 
Figure 46 Aster formation assay: KB cells after transfection with Eg5-Inf7 and control-Inf7 siRNA. 
Polyplexes of targeted (356) and untargeted oligomer (188) were compared. 
Positive aster formation results were also important for further in vivo assays, 
providing a positive read out system for functional siRNA studies. 
3.2.1.5 Polyplex Distribution and Polyplex Retention in vivo 
After the novel multifunctional nanocarrier proved its efficiency in vitro, in vivo 
experiments were carried out to further evaluate the applicability. Initially a 
suitable in vivo testing system for the targeting efficiency had to be evaluated. 
Therefore, both folic acid overexpressing cell lines were injected into the left 
flank or the nape of NMRI mice. Tumor growth was recorded for several days, 
with tumors being palpable one day after subcutaneous injection of tumor cells. In 
contrast to Igrov cells, KB cells continued growing after implantation and reached 
a volume of about 200 mm3 after 10 days (Figure 47). 
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Figure 47 Comparison of tumor growth after subcutaneous injection of KB and Igrov cells: 5 x 106 KB 
and Igrov cells were injected into the left flank or the nape of NMRI mice and tumor volumes were measured 
with a caliper (length x width2/2). In the left graph tumor growth of KB and Igrov cells injected into the flank 
of NMRI mice were compared, whereas in the right graph tumor growth of Igrov cells injected into the flank 
or the nape were compared. Experiments were performed with Katarina Farkasova (veterinary MD thesis, 
LMU 2011). 
In a second experiment the injection site of the tumor cells was evaluated, but 
again Igrov cells failed to demonstrate appropriate tumor growth. Hence, KB cells 
were used for all in vivo experiments. 
For the first experiments polyplexes were injected intratumorally into 
subcutaneous KB tumors of NMRI nude mice to determine the targeting 
efficiency in vivo. NIR fluorescence imaging experiments using Cy7 labeled 
siRNA proved the significantly increased retention of folic acid targeted 
nanoparticles in tumor tissue compared to untargeted particles. Fluorescence 
signals decreased rapidly after intratumoral injection, but Cy7 signals were 
detectable in the tumors of mice injected with the folic acid targeted oligomer for 
120 h (Figure 48). In contrast, free siRNA and untargeted polyplexes were only 
detectable for 24 h. This experiment proved the receptor binding of folic acid 
targeted siRNA carriers in contrast to untargeted carriers after intratumoral 
injection. The small size of the multifunctional nanocarrier system was 
responsible for the fast elution and renal clearance of unbound polyplexes.  
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Figure 48 Fluorescence imaging after intratumoral polyplex injection: Different retention effect of pure 
Cy7 siRNA or Cy7 siRNA complexed by oligomers 356 or 188 after intratumoral injection into KB tumors of 
NMRI mice (n = 3). The diagram shows the calculated amount of Cy7 siRNA in the tumors after ROIs were 
placed on the tumors. Experiments were performed with Laura Schreiner (veterinary MD thesis, LMU 2013). 
As the intratumoral retention was shown to work efficiently the behavior of these 
nanosized particles after systemic application was evaluated. In accordance with 
the intratumoral experiment NIR fluorescence imaging revealed a short circulation 
time of oligomer 356 polyplexes followed by fast renal clearance with strong 
fluorescence signals detectable in the kidney and bladder. This can be explained 
by the small particle size. Significantly, due to the excellent shielding of the 
polyplexes unspecific affinity to tissues like lung, liver or spleen often observed 
with nanoparticles was not detected (Figure 49).  
 
Figure 49 Distribution of nanocarriers after intravenous injection: Fluorescence imaging of oligomer 356 
polyplexes after intravenous injection revealed short circulation times followed by renal clearance. 
Circulation time was compared to different untargeted polyplexes by placing ROIs over the left kidney and 
Cy7 signals were compared after several timepoints. Experiments were performed with Laura Schreiner 
(veterinary MD thesis, LMU 2013). 
Renal clearance was not influenced by the presence/absence of the folate targeting 
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ligand. Compared to other carriers, kidney signals of untargeted and targeted 
nanocarriers increased shortly after polyplex injection and reached a maximum 
after 10 min. Previously mentioned oligomer 386 without fatty acids showed 
longer circulation times with increasing kidney signals after 20 min, whereas the 
very lipophilic U-shape oligomer 278 is cleared through the liver (Figure 49).  
To investigate if bladder signals were caused by pure siRNA or by polyplexes 
L. Schreiner (verterinary MD thesis, LMU 2013) collected urine samples of living 
mice 4 h after polyplexes injection. In a gel shift assay, performed by C. Dohmen, 
free siRNA was only detectable after preincubation of the urine samples with 
TCEP and heparin, demonstrating the stability of the nanocarrier. In summary, the 
particles were very stable in the circulation as no free siRNA could be detected 
after 4 h but the circulation time was short and the polyplexes did not show tumor 
targeting.  
To prolong circulation half life and improve tumor targeting carriers with longer 
precise PEG spacers, increasing the size of nanoparticles from 5.8nm (356) up to 
8.8nm (483) hydrodynamic diameter were injected. These polyplexes have very 
comparable gene silencing efficiency in an eGFPLuc silencing assay (reported by 
T. Fröhlich). However, the nanocarriers with slightly increased sizes behaved very 
similar to oligomer 356 polyplexes after intravenous injection. Strong kidney and 
bladder signals were detected shortly after polyplex injection proving the fast 
clearance through the kidneys (Figure 50).  As polyplex size increased with 
integration of a greater amount of monodisperse PEG spacers, this concept was 
used to further increase polyplex size.  
 
Figure 50 Circulation time of nanocarriers with increasing amount of PEG after intravenous injection: 
Oligomer 356 (1 x PEG24), oligomer 482 (2 x PEG24) and oligomer 478 (3 x PEG24) were compared after 
intravenous injection in NMRI mice (n = 3). Experiments were performed with Laura Schreiner (veterinary 
MD thesis, LMU 2013). 
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Polyplexes with 5 PEG spacers and a size of 11.6 nm (646) showed the longest 
circulation time, while oligomers with 8 PEG spacers and a size of 50.8 nm (647) 
showed circulation times comparable to the standard carrier 356. The short 
circulation time of oligomer 647 with 8 PEG spacer must be influenced by the low 
stability of these polyplexes demonstrated in the gel shift assay. However, the 
circulation time was only slightly prolonged by the incorporation of longer PEG 
chains with limitations due to particle stability (Figure 51). Further backbone 
modifications had to be tested aiming on an increased circulation time.   
 
Figure 51 Circulation time of nanocarriers with increasing amount of PEG after intravenous injection: 
Oligomer 356 (1 x PEG24), oligomer 646 (5 x PEG24) and oligomer 647 (8 x PEG24) were compared after 
intravenous injection in NMRI mice (n = 3). Oligomers were synthesized by U. Lächelt (PhD thesis, LMU). 
Experiments were performed with Laura Schreiner (veterinary MD thesis, LMU 2013). 
The backbone of the oligomeric carrier was modified with fatty acids or tyrosines 
which already showed their positive influence on particle stability and size for 
untargeted oligomers. Therefore, C. Dohmen synthesized oligomers containing 
tyrosine, caprylic acid and stearic acid modifications.  
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Figure 52 Circulation time of nanocarriers with different backbone modifications after intravenous 
injection: Oligomer 356, oligomer 484 (tyrosines), oligomer 481 (caprylic acid) and oligomer 480 (stearic 
acid) were compared after intravenous injection in NMRI mice (n = 3). Experiments were performed with 
Laura Schreiner (veterinary MD thesis, LMU 2013). 
Modifications with tyrosines did not increase particle size and therefore could not 
prolong circulation halflife. Only the liver signals slightly increased for these 
modified nanocarriers. Integration of fatty acids into the backbone led to increased 
liver signals for both nanocarriers 480 and 481 and fatal neuronal toxicity for 
stearic acid modified polyplexes. In conclusion, the modifications could not 
significantly increase circulation half life and improve tumor targeting compared 
to the standard oligomer 356.    
3.2.1.6 Eg5 Knockdown Study in vivo 
For the evaluation of functional gene silencing after intravenous and intratumoral 
application the previously described aster formation assay was used. Although no 
significant detectable amounts of labeled siRNA were found in the tumor tissue 
after intravenous injection, still moderate aster formation was observed using 
Eg5-Inf7 siRNA. On the contrary, mice treated with control-Inf7 siRNA did not 
show any aster formation. The quantification of aster formation is very 
complicated and did not allow a reliable quantitative comparison of targeted and 
untargeted structures. However, the tumor sections displayed in Figure 53 showed 
superior aster formation for mice treated with folic acid targeted nanocarriers 
compared to untargeted carriers.  
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Figure 53 Aster formation after intravenous polyplex injection: 10 days after subcutaneous injection of 
5 x 106 KB cells into NMRI mice (n = 5) polyplexes were injected intravenously. After mice were sacrificed 
DAPI staining in cryo sections displayed aster formation only for Eg5-Inf7 siRNA containing polyplexes. 
Untargeted and targeted polyplexes containing Eg5-Inf siRNA showed moderate aster formation. 
Experiments were performed with Laura Schreiner (veterinary MD thesis, LMU 2013). 
For the detection of mitotic figures after intratumoral polyplex injection an H&E 
staining was established according to the assay published by Judge et al.120. After 
H&E staining, mitotic figures were analyzed and Eg5-Inf7 and control-Inf7 
tumors were compared. Mitotic figures also included dividing cells, whereas aster 
formation only detected cells after mitotic block. Therefore, control siRNA treated 
tumors also displayed mitotic figures to some extent. However, higher amounts of 
mitotic figures were detectable because of the mitotic block in the Eg5-Inf7 
siRNA treated tumors. These results proved the successful target gene silencing 
with the multifunctional nanocarrier system. 
 
Figure 54: Mitotic figures after intravenous polyplex injection: 10 days after subcutaneous injection of 
5 x 106 KB cells into NMRI mice (n = 5) polyplexes were injected intratumorally. Mice were killed 24 h after 
the treatment and tumors were stored in paraformaldehyde. H&E staining of paraffin sections displayed aster 
formation mainly in Eg5-Inf7 siRNA containing polyplexes. Experiments were performed with Laura 
Schreiner (veterinary MD thesis, LMU 2013). 
3.2.2 Methotrexate linked Targeting Oligomers 
After demonstrating successful targeting and siRNA induced gene silencing with 
folic acid linked targeting oligomer 356, the targeting ligand was changed to 
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methotrexate (MTX). MTX has almost the same chemical structure as folic acid 
apart from the positions marked with red circles in Figure 55. Generally, the 
ubiquitous expressed reduced folate carrier is responsible for MTX uptake143, 
whereas in cells overexpressing the folic acid receptor MTX may also be taken up 
through folate receptor mediated endocytosis144.  
 
Figure 55 Chemical structures of the oligomer backbone and methotrexate: Upper structure shows the 
standard oligomer with n = 4 and x = 1. Methotrexate is coupled via γ- (638), like in the case of the folate 
oligomers, or α-carboxy group (642) indicated by the arrows. To improve the methotrexate related effects 
glutamic acid spacer with 2 (639), 4 (640) or 6 (641) glutamic acid molecules between the γ-carboxy group of 
methotrexate and the PEG spacer were integrated. Oligomers were synthesized by U. Lächelt. 
Apart from the use as a targeting ligand, MTX is a well characterized drug applied 
for the treatment of cancer and rheumatoid arthritis. MTX binds with high affinity 
to the enzyme dihydrofolate reductase (DHFR) and inhibits the conversion of 
dihydrofolate to tetrahydrofolate145. Tetrahydrofolate is an important 1-carbon 
carrier, essential for the synthesis of purines, thymidine and methionine. During 
the 1-carbon transfer, tetrahydrofolate is oxidized to dihydrofoalte which is again 
reduced by the enzyme DHFR. Specifically, cells during the synthesis phase are 
harmed by the inhibition of DHFR because of the resulting low levels of 
thymidine and purine bases for DNA and RNA synthesis. Therefore, MTX 
targeted oligomers display the efficacy of this antimetabolic drug and allow the 
delivery of siRNA. MTX targeted oligomers can be combined with therapeutic 
siRNAs, for example Eg5 and Ran siRNA, with siRNAs targeting drug resistance 
mechanism, or with anti inflammatory siRNAs like TNF-α siRNA. Combination 
of MTX and siRNA in one compound ensures the simultaneous active principal 
inside the targeted cell.    
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3.2.2.1 Sensitivity of Different Cell Lines to MTX 
For further oligomer comparison cell lines sensitive and resistant to the treatment 
with MTX had to be identified. Hence, the IC50 values of different cell lines were 
evaluated with pure MTX after 48 h incubation time through an ATP dependent 
assay.  
 
Figure 56 Sensitivity of different cell lines to the treatment with MTX: Several cell lines were tested for 
their sensitivity to MTX treatment. Cell viability was determined by CellTiter Glo measurement 48 h after 
addition of MTX. 
Three cell lines highly sensitive to the treatment with MTX could be identified 
namely Neuro2A cells, A549 and the human epidermoid carcinoma A431. The 
human prostate cancer cell line DU145 showed medium sensitivity, whereas 
HUH7, KB and the human breast cancer cell lines MDA-MB 231 and MCF7 did 
not react to MTX treatment at all (Figure 56).  
3.2.2.2 Cytotoxicity of MTX Oligomers  
Initially the enzyme affinity of pure MTX and MTX linked oligomers was 
compared in a cell free system. For this experiment oligomers coupled through a 
PEG spacer to the α- or γ-carboxy group of MTX were synthesized. Furthermore, 
glutamic acid (E) spacers between the γ-carboxy group and the PEG group were 
integrated, to imitate the naturally occurring addition of glutamic acid molecules 
after cellular uptake to the free γ-carboxy group146. Addition of up to 6 glutamic 
acid groups, mediated by the enzyme folylpolyglutamate synthetase, was reported 
to be of utmost importance, as it enhances the enzyme affinity of MTX. In this 
experimental setting no addition of glutamic acid molecules was possible. 
Enzyme activity was determined through a photometric assay detecting the 
amount of NADPH/H+ at 340 nm. The enzyme activity without inhibitor was set 
to 100% and compared to the activity after addition of MTX or MTX targeted 
oligomers (Figure 57).    
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Figure 57 DHFR activity in a cell free system: Concentrations of NADPH/H+ were measured 
photometricaly to determine the enzyme activity. For the evaluation of the assay different MTX 
concentrations were tested (left panel). Thereafter MTX targeted oligomers 638 (MTX-PEG-STP), 639 
(MTX-2E-PEG-STP), 640 (MTX-4E-PEG-STP), 641 (MTX-6E-PEG-STP), 642 (αMTX-PEG-STP) were 
compared in the same photometric assay (right panel).   
A clear dose dependency was demonstrated for pure MTX in this assay and the 
highest MTX concentrations were chosen for further oligomer comparison. Pure 
MTX and oligomers 640 and 641 performed best in this assay, while oligomers 
638 and 639 showed reduced activity and oligomer 642 showed the lowest 
activity. This activity profile demonstrated the negative effect of α-carboxy 
coupling and the positive effect of oligoglutamate addition.  
Subsequently MTX sensitive A549 cells were treated with pure MTX or MTX 
linked oligomers (Figure 58). In this instance, coupling through the α-carboxy 
group was favorable in comparison to coupling through the γ-carboxy group 
because the free γ-carboxy group allowed oligoglutamate addition. The increased 
enzyme affinity after oligoglutamate addition outweighed the negative effect of α-
carboxy coupling in this cellular assay. Consistently, the synthetic addition of 
oligoglutamates reduced IC50 10 fold compared to the unmodified γ-carboxy 
coupled oligomer 638. 
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Figure 58 IC50 values of MTX and MTX oligomers: A549 cells were treated with pure MTX or oligomers 
638 (MTX-PEG-STP), 639 (MTX-2E-PEG-STP), 640 (MTX-4E-PEG-STP), 641 (MTX-6E-PEG-STP), 642 
(αMTX-PEG-STP) to determine IC50 values. 
In conclusion, coupling via the α-carboxy group (642) improved the IC50 4-fold 
compared to oligomer 638. The addition of glutamic acid spacers 2E, 4E, 6E 
improved the IC50 3.5-fold, 9-fold and 12-fold respectively. This assay 
demonstrates the necessity of the free γ-carboxy group or the pre addition of 
glutamic acid for the effectivity of coupled MTX. The IC50 values however were 
still > 50-fold higher than for free MTX.   
3.2.2.3 Uptake Studies 
Targeting efficiency of oligomers 638, 639, 640, 641 and 642 was determined by 
flow cytometry and compared to oligomer 188 (untargeted) and 356 (targeted by 
folic acid). Folic acid receptor overexpressing KB cells and minimal folic acid 
receptor expressing A549 cells were transfected applying MTX targeted 
oligomers and Cy5 labeled siRNA. After 45 min incubation time, cells were 
trypsinized, collected in FACS buffer (10% FCS in PBS), and analyzed in a flow 
cytometric assay. KB cells showed efficient polyplex uptake for all MTX linked 
oligomers. Uptake efficiency was slightly reduced compared to folic acid targeted 
oligomers, as expected because of the reduced folate receptor binding affinity of 
MTX, compensated by the high receptor density. Strongly reduced uptake of 
MTX linked polyplexes (as compared with folate linked polyplexes) in receptor-
low A549 cells demonstrated the receptor mediated uptake of targeted oligomers. 
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Figure 59 Polyplex uptake determined by flow cytometry: In the left graph polyplex uptake into KB cells 
with high and A549 cells with low folate receptor was compared by flow cytometry. Polyplexes were 
incubated for 45 min on the cells to compare the receptor binding capacity of different oligomers without 
targeting ligand, with folic acid or MTX as targeting ligands. In the right graph oligomers 188 (untargeted), 
356 (folic acid) and 640 (MTX) were compared in different cell lines to determine uptake either through the 
folic acid receptor or the reduced folate carrier.  
Following KB, A549, MCF7, MDA-MB 231 and A431 cells were compared due 
to the uptake of polyplexes targeted by MTX (640) or folic acid (356) (Figure 59 
right panel). Efficient uptake of folic acid targeted and moderately reduced uptake 
of MTX targeted oligomers described for KB cells indicated the involvement of 
solely folate receptors. In contrast, efficient uptake of both targeted oligomers 
indicated the presence of folic acid receptors and reduced folate carriers described 
for A431 cells (right panel, far right lanes). MCF7 and MDA-MB 231 showed 
superior uptake of MTX targeted oligomer 640, indicating the absence of folate 
receptor and uptake solely via the reduced folate carrier. Both targeting assays 
revealed receptor mediated uptake for MTX targeted oligomers (Figure 59). The 
experiment in combination with the previous testing of folic acid receptor levels 
indicated polyplex uptake for the MTX oligomers through the folic acid receptor 
in KB cells, the reduced folate carrier in MCF7 and MDA-MB 231 cells and a 
combination of both in A431 cells.  
3.2.2.4 GFP Knockdown in KB Cells   
For the detection of marker gene silencing, KB-eGFPLuc cells were chosen due to 
their high expression of folic acid receptors and their moderate susceptibility to 
the treatment with MTX. Knockdown after GFP siRNA transfection was 
compared to control siRNA and pure oligomer. To demonstrate efficient targeting 
MTX targeted and untargeted polyplexes were compared after an incubation time 
of 45 min.   
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Figure 60 Transfection experiments: KB-eGFPLuc cells were transfected with MTX targeted (638, 639, 
640, 641, 642) and untargeted (188) polyplexes. GFP and control siRNAs modified with the lytic peptide Inf7 
were used because previous experiments demonstrated the necessity of an endosomolytic siRNA. Polyplexes 
were mixed at an N/P of 16 with 200 ng siRNA per well and incubated for 45 min. 
The results demonstrated efficient target gene knockdown mediated through MTX 
linked oligomers similar as previously shown for folate linked oligomers, whereas 
untargeted oligomers did not show eGFPLuc silencing (Figure 60). In contrast to 
folate-linked oligomers, MTX oligomers and control siRNA polyplexes caused 
comparable unspecific eGFPLuc silencing (50% luciferase reduction) due to 
carrier related toxicity. In conclusion, all MTX linked oligomers showed similar 
and efficient marker gene knockdown in the GFP siRNA group with moderate 
toxicity caused by the MTX oligomers.  
3.2.2.5 Combined Toxicity of MTX/siEG5 Polyplexes 
Polyplexes consisting of MTX oligomer 640 and Eg5-Inf7 siRNA were mixed to 
demonstrate combined toxicity of the carrier and therapeutic siRNA. A431 cells 
were chosen because of their high susceptibility to MTX treatment and the 
effective uptake of MTX targeted oligomers demonstrated in the previous 
experiments. Cell viability of A431 cells after transfection with pure polymer or 
polyplexes containing either control or Eg5 siRNA was compared. 
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Figure 61 Cell viability assay: A431 cells transfected with control oligomer 188, folate oligomer 356 or 
MTX oligomer 640 polyplexes containing either Eg5 or control siRNA were compared due to the cell 
viability. Oligomer concentration of 100 µM was calculated and the siRNA concentration was adjusted to 
result in an N/P of 16.  
Transfection with Eg5 siRNA in combination with MTX targeted oligomer 640 
and folic acid targeted oligomer 356 resulted in reduced cell viability compared to 
buffer treatment (Figure 61). The pure MTX oligomer reduced cell viability very 
effectively, whereas control siRNA polyplexes displayed reduced effects on cell 
viability. The combination of oligomer 640 and Eg5 siRNA improved the 
cytotoxic effect indicating the potential of this combination. Consistent with the 
previous marker gene experiment oligomer 188 did not mediate any effect 
because of the short incubation time. 
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4 DISCUSSION 
4.1 Evaluation of Monodisperse, Sequence Defined siRNA 
Carriers 
Technological aspects, such as tumor targeting and insufficient delivery into the 
cytosol, are hindering the medical application of siRNA in cancer therapy147. To 
overcome this hurdle we built on a large library of sequence defined 
biodegradable oligomers for siRNA delivery133. This approach allowed the 
comparison of several oligomers to establish structure-activity relations for 
siRNA carriers75. Many modifications of the biodegradable oligomers, improving 
siRNA binding, cellular uptake and endosomal release of the polyplexes have 
been reported136. For further experiments two lipo-oligomers (49 with T-shape 
and 229 with i-shape topology) and a branched oligomer (386) were selected. 
These oligomers fulfil the previously defined requirements for successful siRNA 
delivery and were compared for silencing of the marker gene eGFPLuc and two 
therapeutic targets, Ran and Eg5.  
4.1.1 Oligomer Evaluation in vitro and in vivo  
Comparison of oligomer 49 to the gold standards Lipofectamine 2000 and PEI-
Succ10 displayed comparable high gene silencing efficiency for all carriers. The 
following comparison of oligomers 49, 229 and 386 revealed similar knockdown 
efficiency for the structurally different oligomers. This was an important fact as 
differences concerning the in vivo efficacy of these in vitro functional carriers 
should be demonstrated. Besides eGFPLuc also Eg5 and Ran silencing were 
evaluated in vitro to establish a therapeutic in vivo oligomer screening system. 
The experiments highlighted clear differences between the in vitro gene silencing 
and the corresponding in vivo antitumoral efficiencies of these carriers.  
Both antitumoral siRNAs, Eg5 and Ran, showed specific target gene knockdown 
on mRNA and protein level. Interestingly, target gene knockdown only persisted 
for a short period of time. Reduced mRNA levels were detectable 24 and 48 h 
after siRNA transfection, whereas after 72 h Eg5 mRNA levels of control and Eg5 
siRNA transfected cells were on the same level. Ran knockdown was also 
detectable after 24 and 48 h, but after 72 h an up-regulation of Ran mRNA was 
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observed. The fast growth rate of Neuro2A cells and the fact that successful 
transfection led to removal of cells by cell death, explained the short duration of 
target gene knockdown compared to other siRNA studies148. Eg5 knockdown 
resulted in aster formation and changed cell cycle stages compared to control 
siRNA or buffer transfected cells. DAPI and tubulin staining revealed typical 
mitotic figures, due to the blocked separation of the centrosomes after Eg5 
knockdown. Furthermore, increased G2 peaks and increasing sub G1/G0 peaks 
demonstrated the mitotic arrest, followed by cell death. In contrast, Ran 
knockdown only led to increased sub G1/G0 peaks. These findings were 
consistent with the biological mechanism of the target gene inhibition and 
demonstrated the antitumoral potential of both siRNAs. Furthermore, a cell 
viability assay confirmed the therapeutic tumor cell killing by both siRNAs in 
vitro. To evaluate the two target genes in vivo, three different siRNA 
concentrations were compared for intratumoral injection75. Only oligomer 49 
polyplexes with 50 µg siRNA per injection showed significant reduction of tumor 
growth in the Eg5 siRNA group compared to control siRNA treatment. In 
contrast, polyplexes with 25 and 12.5 µg siRNA per injection did not result in 
reduced tumor growth. This relatively high amount of siRNA is required because 
of the fast tumor growth after subcutaneous injection of 5 x 106 Neuro2A cells. 
Experiments comparing Eg5 and Ran siRNA were performed according to the 
previous dose finding experiment using oligomer 49. Mitotic arrest after 
transfection with Eg5 siRNA and apoptotic TUNEL staining after transfection 
with Ran siRNA indicated successful target gene knockdown in vivo. Both 
therapeutic siRNAs reduced tumor growth compared to control siRNA treatment. 
Control siRNA polyplexes had some inhibitory effect on tumor growth compared 
to buffer treated tumors, but did not result in significant prolonged survival. Ran 
siRNA polyplexes mediated the best antitumoral effects. Therefore, Ran silencing 
led to slower tumor growth rates and prolonged survival (28 days) compared to 
Eg5 mRNA knockdown (25 days). This might be explained by the effects of Ran 
(role in nuclear transport) knockdown on cells in all cell cycle stages, whereas 
knockdown of Eg5 (role in mitotic chromosome separation) only affects dividing 
cells. Due to these findings Ran siRNA was used for further in vivo experiments.  
For the oligomer comparison the three previously described, diversely shaped 
carriers were selected because of their high gene silencing efficacy in vitro. 
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Polyplex size and stability varied depending on the applied oligomer. Both lipo-
oligomers formed polyplexes in a range of 20-50 nm, whereas the branched 
oligomer 386 formed large particles with a size of about 600 nm. The lipo-
oligomers possess higher polyplex stability than the larger branched oligomer 386 
particles. This was confirmed through the findings by imaging polyplexes 
containing Cy7 labelled siRNA after intratumoral injection. Oligomers 49 and 229 
showed high intratumoral Cy7 signals for 48 h after polyplex injection, whereas 
Cy7 signals for oligomer 386 polyplexes decreased in this time range. The 
fluorescence signals in the kidneys (indicating slow release of free siRNA) 
confirm the partial instability of oligomer 386 polyplexes. Polyplex stability 
however was not critical and apparently sufficient in intratumoral administration 
with dosing at every 3 days, as antitumoral efficacy did not correlate with 
polyplex stability. After intravenous injection oligomers 49 and 229 showed 
accumulation in the liver > kidneys > tumor > lung detected by fluorescence 
microscopy of organ sections. Oligomer 229 showed superior tumor accumulation 
compared to oligomer 49. This could be influenced due to the lower zeta potential 
of oligomer 229 polyplexes, leading to reduced interaction with blood 
components and therefore increasing tumor accumulation after intravenous 
injection. 
In vitro knockdown efficiencies determined by qPCR and Western blot after Eg5 
and Ran silencing were in consistency with the marker gene studies demonstrating 
the same level of target gene silencing for the three oligomers. Furthermore, the 
effects on tumor cell viability and the kinetics of target gene knockdown were 
evaluated. Comparing the three oligomers, different silencing kinetics were 
detectable on protein level after 24 h, demonstrating the fastest Eg5 and Ran 
protein silencing mediated by oligomer 386. In accordance with these findings, 
oligomer 386 polyplexes containing either Eg5 or Ran siRNA decreased tumor 
cell viability at 48 h best. After 72 h all polyplexes containing therapeutic Eg5 or 
Ran siRNA mediated significant tumor cell killing, with oligomer 386 mediating 
the strongest effects. To compare antitumoral in vitro and in vivo efficacy of the 
three oligomers, an intratumoral siRNA treatment was started. Oligomer 229 
failed to reduce tumor growth comparing the Ran siRNA and the control siRNA 
groups. Oligomer 49 Ran siRNA polyplexes showed significantly reduced tumor 
growth compared to control siRNA polyplexes after 3 but not after 2 intratumoral 
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polyplex injections per week, indicating the necessity of frequent polyplex dosing 
in the fast growing Neuro2A tumor model. The best tumor growth reduction was 
mediated by oligomer 386. Tumor growth and tumor weights were significantly 
reduced in the Ran siRNA compared to the control siRNA transfected tumors in 
two independent experiments. In sum, oligomer 386 reduced tumor volume best, 
followed by oligomer 49, whereas oligomer 229 was inactive for local tumor 
treatment in vivo. 
The results demonstrate a discrepancy of the three tested oligomers in their in 
vitro and in vivo activity. Although all oligomers showed efficient target gene 
mRNA and protein knockdown in several in vitro assays, only oligomer 386 and 
to some extent oligomer 49 mediated reduced tumor growth in vivo. Only the fast 
knockdown kinetic and the high antitumoral activity of oligomer 386 in vitro can 
be correlated to the high in vivo efficiency. Of note, 386 forms the largest siRNA 
polyplexes with only moderate stability. These findings demonstrated the 
importance of in vivo testing for the development of potent siRNA delivery 
agents. Future experiments should demonstrate efficient tumor growth reduction 
after intravenous polyplex injection. For this reason stabilisation through the 
incorporation of tyrosines136 or PEGylation and targeting116,149 will be important 
factors. 
4.1.2 Tyrosine Trimer Stabilized T-shape Oligomers 
Improved polyplex stability plays an important role especially for the successful 
delivery of nucleic acids after intravenous injection141. Hence, certain 
components, like hydrophobic dioleic acid motifs and cysteines, were 
incorporated in the previous oligomeric structures to ensure polyplex stabilization. 
To further enhance polyplex stability an oligotyrosine motif was integrated into 
the sequence defined oligomers150. Subsequently, the stability and silencing 
efficiency of polyplexes containing cysteines, a dioleic acid motif, an 
oligotyrosine modification or a combination of these components were compared. 
Oligomers modified with solely tyrosines were less efficient in binding nucleic 
acid and displayed decreased transfection efficiency. All other oligomers, except 
the control oligomer 216, showed efficient eGFPLuc silencing. In conclusion, the 
efficient siRNA transfection requires the combination of two different stabilizing 
components. 
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Additionally, polyplex stability was analyzed in 90% serum and demonstrated 
superior stability of oligomers with lateral oligotyrosines to oligomers with 
terminal cysteines. Oligomers combining oligotyrosines and cysteines in the 
periphery displayed the best polyplex stability. On account of these beneficial 
properties, the in vivo distribution of Cy7 labeled siRNA polyplexes after 
intravenous injections was monitored. Oligomers 468 and 464 quenched the 
fluorescent signal of the Cy7-labeled siRNA, making an in vivo comparison of 
these polyplexes impossible due to detection reasons. Even though, the oligomers 
quenched the signal, no free Cy7-labeled siRNA was detected in the kidneys or 
the bladder. This allowed the conclusion that the polyplexes were still intact 
during the first hour. NIR fluorescence imaging revealed short circulation times 
followed by a fast renal clearance116,151 for free siRNA with a hydrodynamic 
radius of approximately 2.3 nm and for oligomer 216 polyplexes. As the sizes of 
the control polyplexes were larger than the renal filtration limit, dissociation must 
have occurred before elimination through the kidneys. According to previous 
stability assays oligomer 333 polyplexes showed partial instability with stable 
polyplexes accumulating in the liver and free siRNA being detectable in the 
kidneys after intravenous injection. In contrast, oligomers 49, 332, and 454 
polyplexes revealed a prolonged presence of complexed siRNA in the circulation 
compared to free siRNA and control oligomers. The modification with fatty acids 
increased polyplex accumulation in the liver152. Consistent with the high in vitro 
stability, longer circulation times of oligomers 332 and 454 polyplexes were 
recorded compared to oligomer 49 polyplexes. In summary, the higher serum 
stability of oligotyrosine modified polyplexes was beneficial for in vivo 
distribution, but oligomer characteristics, like the hydrophobicity, also played an 
important role.  
In accordance with the previously established intratumoral treatment, oligomer 
332, 468, 454 and 464 polyplexes were compared to oligomer 49 polyplexes. 
Again Neuro2A tumor bearing NMRI mice were treated with Ran or control 
siRNA polyplexes twice a week, in total 5 times. Oligomers 49, 454 and 464 
failed to mediate reduced tumor growth in the Ran siRNA group compared to the 
control siRNA group. Oligomer 464 polyplexes caused tumor necrosis making the 
bioluminescence evaluation of tumor growth impossible. In contrast, treatment 
with oligomer 468 and 332 Ran siRNA polyplexes reduced the tumor volume 
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compared to control siRNA polyplexes. These data confirmed the previous 
experiment demonstrating the efficacy of less stable polyplexes for the 
intratumoral treatment of Neuro2A tumor bearing mice. However, these highly 
stable polyplexes with increased circulation times will improve tumor 
accumulation after intravenous injection. In conclusion, the incorporation of 
oligotyrosine motifs improved polyplex stability of T-shaped oligomers and is an 
important option for the in vitro and in vivo stabilization of other carriers.   
4.2  Evaluation of Targeted Nanocarriers for siRNA Delivery 
On the contrary to polyplexes without targeting ligands, incorporation of targeting 
ligands allows target cell specific polyplex delivery153. Specifically shielded 
particles with low zeta potentials are dependent on targeting ligands, because the 
incorporation of targeting ligands regains polyplex cell interaction in a receptor 
specific way. For in vivo applications targeted structures with low zeta potentials 
are favored due to reduced unspecific interactions leading to reduced side effects. 
Targeted carriers were also synthesized by solid-phase-assisted macromolecule 
assembly, enabling the incorporation of different building blocks, PEG chains and 
targeting ligands116.  
4.2.1 Nanocarriers with Targeting Ligand Folic Acid 
The targeted nanocarriers were thoroughly analyzed, and the requirement of every 
single substructure was demonstrated. A cell line screen revealed only KB and 
Igrov cells highly expressing the folic acid receptor. Therefore, KB and Igrov 
cells were chosen for transfection and targeting experiments, demonstrating the 
high targeting specificity of the nanocarrier. Furthermore, the beneficial effect of 
influenza-peptide modified siRNA could be demonstrated in a marker gene 
silencing assay. In contrast to the high amounts of nanocarrier required for 
efficient endosomal escape the application of influenza peptide modified siRNA 
enabled efficient siRNA silencing at low N/P ratios. Moreover, the titration of 
polyplex or siRNA concentrations demonstrated the high efficiency of these 
nanocarriers down to a siRNA concentration of 6 nM. The comparison with the 
gold standard Lipofectamine 2000 revealed superior efficiency for the targeted 
nanocarrier system. In accordance, with the eGFPLuc screen silencing of the 
therapeutic protein Eg5 demonstrated aster formation only for targeted 
nanocarriers complexing Eg5-Inf7 siRNA. 
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For in vivo experiments KB cells were chosen because they developmened tumors 
of 200 mm3 after 10 days incubation time. In contrast, subcutaneous injection of 
Igrov cells did not result in fast growing tumors. Following in vivo experiments 
demonstrated tumor retention for 120 h after intratumoral injection of folic acid 
targeted nanocarriers. In contrast, untargeted nanocarriers and free siRNA were 
washed out of the tumor within 24 h and showed significantly reduced tumor 
retention. In consistency, with previous in vitro experiment this experiment 
demonstrated the positive effect of folic acid targeting in vivo.  
After intravenous injection the nanocarriers complexing Cy7 labeled siRNA were 
detectable by NIR imaging in the circulation without unspecific accumulation in 
non targeted tissue such as liver, lung, or spleen. However, the nanosized 
appearance (about 5.8 nm hydrodynamic diameter) of this functionally active 
carrier caused fast renal clearance, compared to the bigger branched oligomer 386 
polyplexes and the very lipophilic polyplexes of oligomer 278. KB tumors where 
implanted into the neck of NMRI mice, preventing the interaction of tumor and 
kidney signals. In this experiment kidney and bladder signals where caused by 
intact polyplexes and not by pure siRNA. Gel shift assays of urine samples taken 
4 h after polyplex injection proved the stability of the nanocarriers as free siRNA 
was only detectable after heparin and TCEP treatment. To increase circulation 
times and improve tumor targeting structures with longer PEG spacers, tyrosine, 
or fatty acid modification were synthesized. However, the resulting nanocarriers 
did not positively influence the in vivo distribution. Incorporation of longer PEG 
spacers increased particle size but reduced polyplex stability especially for 
oligomer 647 with 8 x more PEG than the standard oligomer 356. Oligotyrosines 
did not influence particle size and circulation time at all, only a moderate liver 
accumulation in consequence to their lipophilic character was detectable. 
Nanocarriers with fatty acid modification showed the worst effect with caprylic 
acid incorporation leading to liver accumulation of the polyplexes and stearic acid 
modification causing fatal side effects. Hence, the standard oligomer 356 was 
used for functional in vivo studies.  
Intravenous injection of targeted and untargeted nanocarriers with Eg5-Inf7 
siRNA showed histological aster formation 24 h after polyplex injection. 
Presumably, very little amounts of the nanocarriers undetectable by NIR imaging 
reached the tumor and caused target gene knockdown because of their high 
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efficiency. Apparently, targeted nanocarriers are more efficient as untargeted, but 
the quantification of aster formation was very complicated because of intense 
regional differences in this assay. 
Consequently, Eg5 knockdown was detected by H&E staining after intratumoral 
injection. This approach allowed a semi quantitative evaluation of mitotic figures. 
In contrast to the previously described aster formation, the analysis of mitotic 
figures is not a positive read out system, because also mitotic cells are detected. 
The analysis of H&E stained sections revealed a strong increase of mitotic figures 
after injection of Eg5-Inf7 siRNA incorporating nanocarriers compared to control-
Inf7 siRNA nanocarriers. Both assays proved successful siRNA delivery and Eg5 
silencing in vivo, demonstrating the high potential of this multifunctional 
nanocarrier.  
4.2.2 Nanocarriers with Targeting Ligand Methotrexate 
Pharmaceutically relevant drugs, like methotrexate with high structure similarity 
to folic acid, can be used for targeting in the multifunctional nanocarrier system. 
This approach combines the effect of a classical drug with the great potential of 
siRNA induced gene silencing. Several siRNAs can be included into the 
nanocarrier addressing targets related to the illness or causing drug resistance. The 
combination could allow dose reduction of the chemostatic drug yielding in 
reduced side effects or increased overall efficiency. Chemical synthesis of 
functionalized nanocarriers was complicated because the coupled drug has to 
maintain its efficiency.  
Several cancer cell lines were screened and three cell lines (A549, A431, 
Neuro2A) were identified to be highly sensitive to MTX treatment. We utilized 
the human alveolar A549 cells to screen the IC50 values of several MTX targeted 
oligomers either coupled through the α- or γ-carboxy group. To simulate the 
addition of glutamic acid and to improve the enzyme affinity after cellular uptake 
different glutamic acid spacers were introduced into the structure. At first DHFR 
inhibition was tested in a cell free system, demonstrating successful enzyme 
inhibition for MTX targeted carriers. Coupling through the α-carboxy group was 
unfavorable in a cell free system resulting in reduced enzyme affinity for the α-
carboxy modified carrier. In contrast, the α-carboxy modification was superior to 
the γ-carboxy modification in A549 cells, allowing the adhesion of glutamic acid 
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molecules after cellular uptake. In accordance, the use of glutamic acid spacers for 
γ-carboxy modified MTX carriers resulted in 10-fold lower IC50 values compared 
to γ-carboxy modified MTX carriers without glutamic acid spacers. However, the 
IC50 values of the best performing oligomer 641 with 6 glutamic acid spacers was 
still 60-fold higher than the IC50 value of pure MTX. Incorporation of acid labile 
or reducible bonds between PEG spacer and MTX could further reduce the IC50 
values and improve the efficiency.  
Receptor specificity was demonstrated through flow cytometric experiments. The 
experiment demonstrated efficient uptake of all MTX linked carriers into folic 
acid receptor highly expressing KB cells, whereas the uptake in A549 cells with 
low folic acid receptor level was significantly reduced. In comparison to folic acid 
linked nanocarriers the uptake was moderately decreased displaying the reduced 
receptor affinity. Further flow cytometric experiments were performed comparing 
the uptake of MTX and folic acid linked nanocarriers to distinguish between the 
uptake through folic acid receptors or the reduced folate carriers. KB cells 
expressed the folic acid receptor (Figure 41) and preferable took up folic acid 
targeted carriers154. In contrast, MCF7 and MDA-MB 231 cells did not express 
the folic acid receptor determined in a flow cytometric assay. Therefore, folic acid 
linked nanocarriers were not taken up and MTX linked nanocarriers were 
presumably primarily taken up through the reduced folate carrier. A431 cells 
expressed both, folic acid receptors and reduced folate carriers, and took up folic 
acid and MTX linked oligomers with equal efficiency.  
Transfection experiments were performed in KB cells moderately susceptible to 
MTX treatment because high carrier mediated toxicity would be unsuitable for the 
detection of target gene knockdown. All targeted siRNA binding nanocarriers 
mediated specific eGFPLuc silencing and proved superior efficiency over 
untargeted nanocarriers. Besides efficient targeting, all MTX nanocarriers 
mediated MTX specific toxicity detectable after control siRNA and pure carrier 
transfections. In conclusion, the assays demonstrated successful receptor binding, 
DHFR inhibition and siRNA delivery for the MTX targeted nanocarriers. 
Consequently, the most efficient nanocarrier 640 was combined with Eg5-Inf7 
siRNA for the transfection of A431 cells. Pure and control siRNA binding 
nanocarrier 640 significantly reduced cell viability compared to pure and Eg5 
binding untargeted nanocarrier 188, demonstrating the MTX related toxicity. 
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According to the previous experiments, the combination of Eg5 siRNA and MTX 
linked nanocarrier 640 showed the strongest effect and evidenced the proof of 
concept for the combination of MTX linked nanocarriers and therapeutic siRNAs. 
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5 SUMMARY 
Nucleic acid therapies, such as siRNA induced gene silencing, are considered as 
promising options for novel treatments of cancer and several other incurable 
diseases5,11,155-157. Successful siRNA application is hampered due to the difficult 
applicability of nucleic acids in general and the low serum stability of siRNAs in 
particular. Advances in carrier design, including polymers112,133,158 show the 
potential to overcome these problems and to establish this innovative class of 
drugs. In this thesis several in vitro and in vivo assays were established to 
demonstrate successful application of sequence defined, biodegradable oligomers 
for siRNA delivery.  
Several hundred monodisperse oligomers were synthesized by solid-phase-
assisted macromolecule assembly and screened to define structure-activity 
relationships. Three structurally diverse oligomers were selected and qPCR and 
Western blot assays were established to demonstrate successful target gene 
knockdown for the therapeutic relevant Eg5 and Ran siRNAs. In accordance with 
the previous screening assay, lipo-oligomers 49 (T-shape), 229 (i-shape) and the 
branched oligomer 386 mediated successful and efficient target gene silencing. 
Furthermore, flow cytometric, histological, and cell viability assays demonstrated 
the high therapeutic potential of Eg5 (aster formation, G2 arrest, cell death) and 
Ran (cell death) siRNA. First in vivo assays helped to define the required doses 
for intratumoral polyplex injections and enabled the comparison of Eg5 and Ran 
siRNA in vivo.  Silencing of Ran showed superior therapeutic effects with 
reduced tumor growth and prolonged survival compared to all other groups. The 
comparison of different oligomers revealed oligomer 386 as the most in vivo 
effective oligomer although all oligomers showed efficient target gene 
knockdown in vitro. In summary, this demonstrated the difficult correlation of in 
vitro and in vivo activity and proved the necessity of in vivo experiments for the 
design of efficient siRNA carriers. 
Additional integration of oligotyrosine motifs into the carriers resulted in 
improved polyplex stability detectable in serum gel shifts in vitro and through 
NIR imaging in vivo. After intratumoral injection high polyplex stability was not 
the most critical parameter. Therefore, this polyplexes did not improve Ran 
silencing. Exchange of terminal cysteines by oligotyrosine motifs slightly 
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increased the stability and showed Ran silencing after intratumoral application. In 
conclusion, the integration of oligotyrosines improves polyplex stability, but very 
high polyplex stability is not favorable for effective gene silencing after 
intratumoral injection. 
Effective shielding and the addition of folic acid as ligand for targeting in 
combination with siRNA coupled to the lytic influenza peptide resulted in highly 
efficient nanocarriers. Several experiments proved the necessity of every single 
domain like cysteines for stabilisation, folic acid for targeting and influenza 
peptide for endosomal escape. Further studies revealed the impressive targeting 
efficiency of this nanocarrier system after intratumoral injection and the short 
circulation time without any undesired accumulation after intravenous injection. 
Low tumor accumulation was detected after intravenous injection affected by the 
poor blood flow in the implanted KB tumors. However, nanocarriers binding Eg5-
Inf7 siRNA selectively showed aster formation indicating a low accumulation of 
nanocarriers in the tumor. Several modifications of the carrier did not result in the 
desired increased size and stability of the carrier system, but the synthetic 
approach and the increasing knowledge will allow the integration of further 
modifications to develop a more efficient nanocarrier. 
The synthetic approach also allowed the substitution of folic acid through other 
targeting ligands. The integration of the drug methotrexate extended targeting to 
the reduced folate carrier and combined targeting with a cytostatic activity of this 
ligand. Several chemically modified nanocarriers were tested to demonstrate the 
inhibition of dihydrofolate reductase and the targeting efficiency. In summary, the 
integration of a four glutamic acid long spacer between the PEG chain and 
methotrexate showed the best overall activity. This compound in combination 
with therapeutic Eg5 siRNA was tested in a cell viability assay and demonstrated 
superior efficiency compared to all controls. Improved oligomer backbones, as 
discussed for folic acid targeted nanocarriers, will turn this concept into a highly 
efficient siRNA carrier with cytostatic activity. 
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6 APPENDIX 
6.1 Abbreviations 
Ago2 Argonaute protein 2 
brPEI Branched PEI 
CapA Caprylic acid 
CCD Charge-coupled Device 
Cy3 Cyanine dye (ex. 550 ; em. 570) 
Cy5 Cyanine dye (ex. 650 ; em. 670) 
Cy7 Cyanine dye (ex. 743; em. 767) 
DAPI 4',6-diamidino-2-phenylindole 
DHFR Dihydrofolatereductase 
DMEM Dulbecco`s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DSP Bifunctional crosslinker 
eGFP Enhanced green fluorescend protein 
EDTA Ethylenediaminetetraacetic acid 
EGF/EGFR Epidermal growth factor/ Epidermal growth factor 
receptor 
Eg5 Eglin 5, or KSP, Kinesin spindle protein 
EPR effect Enhanced permeability and retention effect 
EtBr Ethidium bromide 
FCS Fluorescence correlation spectroscopy 
FCS Fetal calf serum 
FolA Folic acid 
FR Folic acid receptor 
GDP/GTP Guanosine-diphosphat/ Guanosine-triphosphat 
GMP Good manufacturing practice 
Appendix     96 
 
GTP Glutaryl-tetraethyl-pentamine 
GTT Glutaryl-triethyl-tetramine 
HA-2 Hemagglutinin subunit 2 
HBG Hepes buffered glucose 
HEPES N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic 
acid) 
HES Hydroxyethyl starch 
INF7 Subunit of the influenca peptide 
i.p. Intraperitoneal(ly) 
i.v. Intravenous(ly) 
kDa Kilo Dalton 
LCA Leber congenital amaurosis 
LF2000 Lipofectamine 2000 
lPEI Linear polyethylenimine 
Luc Luciferin 
LSM Laser scanning microscopy 
MDR Multidrug resistance 
miRNA Micro ribonucleic acid 
mRNA Messenger ribonucleic acid 
MDA-5 Melanoma differentiation associated protein 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
MTX Methotrexate 
N/P Polymer nitrogen to nucleic acid phosphate ratio 
NIR Near infrared   
OEI Oligo ethylene imine 
ON Oligo nucleotide 
PAMAM Polyamidoamine dendrimer 
PBS Phosphate buffered saline 
pDNA Plasmid deoxyribonucleic acid 
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 PEG Polyethylene glycol 
PEG24 Polyethylene glycol with exactly 24 monomers  
PEI-Succ10 Branched polyethyleneimine modified with succinic 
acid 
pHPMA Polyhydroxypropylmethacrylate 
PLL Polylysine 
Ptp Phthalyl-tetraethyl-pentamine 
qPCR Quantitative polymerase chain reaction 
rh Hydrodynamic radius 
Ran RAS related nuclear protein 
RIG-1 Retinoic acid inducible protein 
RISC Ribonucleic acid induced silencing complex 
RLC RISC loading complex 
RNA Ribonucleic acid 
RNAi Ribonucleic acid interference 
ROI Region of Interest 
S.E.M. Standard Error of the Mean 
SCID Severe combined immunodeficiency 
siRNA Small interfering ribonucleic acid 
SteA Stearic acid 
Stp Succinyl-tetraethylen-pentamine 
TBE-buffer Tris-Boric acid-EDTA-buffer 
TCEP Tris(2-carboxyethyl)phosphine 
TFA Trifluoroacetic acid 
TfR Transferrin receptor 
TLR Toll like receptor 
TRBP  Transactivating response RNA binding protein 
Y3 Tyrosin-Tyrosin-Tyrosin (Tyrosin trimer) 
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Hadwiger P, Wagner E (2011) Solid-phase synthesis of sequence-defined T-, i-, 
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